1
|
Zheng J, Wheeler E, Pietzner M, Andlauer TFM, Yau MS, Hartley AE, Brumpton BM, Rasheed H, Kemp JP, Frysz M, Robinson J, Reppe S, Prijatelj V, Gautvik KM, Falk L, Maerz W, Gergei I, Peyser PA, Kavousi M, de Vries PS, Miller CL, Bos M, van der Laan SW, Malhotra R, Herrmann M, Scharnagl H, Kleber M, Dedoussis G, Zeggini E, Nethander M, Ohlsson C, Lorentzon M, Wareham N, Langenberg C, Holmes MV, Davey Smith G, Tobias JH. Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome-Wide Association Meta-Analysis Followed by Mendelian Randomization. Arthritis Rheumatol 2023; 75:1781-1792. [PMID: 37096546 PMCID: PMC10586470 DOI: 10.1002/art.42538] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Revised: 03/22/2023] [Accepted: 04/18/2023] [Indexed: 04/26/2023]
Abstract
OBJECTIVE In this study, we aimed to establish the causal effects of lowering sclerostin, target of the antiosteoporosis drug romosozumab, on atherosclerosis and its risk factors. METHODS A genome-wide association study meta-analysis was performed of circulating sclerostin levels in 33,961 European individuals. Mendelian randomization (MR) was used to predict the causal effects of sclerostin lowering on 15 atherosclerosis-related diseases and risk factors. RESULTS We found that 18 conditionally independent variants were associated with circulating sclerostin. Of these, 1 cis signal in SOST and 3 trans signals in B4GALNT3, RIN3, and SERPINA1 regions showed directionally opposite signals for sclerostin levels and estimated bone mineral density. Variants with these 4 regions were selected as genetic instruments. MR using 5 correlated cis-SNPs suggested that lower sclerostin increased the risk of type 2 diabetes mellitus (DM) (odds ratio [OR] 1.32 [95% confidence interval (95% CI) 1.03-1.69]) and myocardial infarction (MI) (OR 1.35 [95% CI 1.01-1.79]); sclerostin lowering was also suggested to increase the extent of coronary artery calcification (CAC) (β = 0.24 [95% CI 0.02-0.45]). MR using both cis and trans instruments suggested that lower sclerostin increased hypertension risk (OR 1.09 [95% CI 1.04-1.15]), but otherwise had attenuated effects. CONCLUSION This study provides genetic evidence to suggest that lower levels of sclerostin may increase the risk of hypertension, type 2 DM, MI, and the extent of CAC. Taken together, these findings underscore the requirement for strategies to mitigate potential adverse effects of romosozumab treatment on atherosclerosis and its related risk factors.
Collapse
Affiliation(s)
- Jie Zheng
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, and Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the People's Republic of China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, and MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of BristolBristolUK
| | - Eleanor Wheeler
- MRC Epidemiology Unit, Institute of Metabolic ScienceUniversity of Cambridge School of Clinical MedicineCambridgeUK
| | - Maik Pietzner
- MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK, and Computational Medicine, Berlin Institute of Health at Charité–Universitätsmedizin BerlinBerlinGermany
| | - Till F. M. Andlauer
- Department of Neurology, Klinikum rechts der Isar, School of MedicineTechnical University of MunichMunichGermany
| | - Michelle S. Yau
- Marcus Institute for Aging Research, Hebrew SeniorLifeHarvard Medical SchoolBostonMassachusetts
| | | | - Ben Michael Brumpton
- K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, and HUNT Research Centre, Department of Public Health and Nursing, NTNUNorwegian University of Science and TechnologyLevangerNorway
| | - Humaira Rasheed
- MRC IEU, Bristol Medical School, University of Bristol, Bristol, UK, and HUNT Research Centre, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Levanger, Norway, and Division of Medicine and Laboratory Sciences, Faculty of MedicineUniversity of OsloOsloNorway
| | - John P. Kemp
- MRC IEU, Bristol Medical School, University of Bristol, Bristol, UK, and Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia, and The University of Queensland Diamantina InstituteThe University of QueenslandBrisbaneQueenslandAustralia
| | - Monika Frysz
- MRC IEU, Bristol Medical School, University of Bristol, and Musculoskeletal Research UnitUniversity of BristolBristolUK
| | - Jamie Robinson
- MRC IEU, Bristol Medical SchoolUniversity of BristolBristolUK
| | - Sjur Reppe
- Unger‐Vetlesen Institute, Lovisenberg Diaconal Hospital and Department of Plastic and Reconstructive Surgery, Oslo University Hospital and Department of Medical BiochemistryOslo University HospitalOsloNorway
| | - Vid Prijatelj
- Department of Internal MedicineErasmus MC University Medical CenterRotterdamThe Netherlands
| | | | - Louise Falk
- MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK, and Computational Medicine, Berlin Institute of Health at Charité–Universitätsmedizin BerlinBerlinGermany
| | - Winfried Maerz
- Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Austria, and SYNLAB Academy, SYNLAB Holding Deutschland GmbH and Vth Department of Medicine (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Diabetology), Medical Faculty MannheimUniversity of HeidelbergMannheimGermany
| | - Ingrid Gergei
- Vth Department of Medicine (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Diabetology), Medical Faculty Mannheim, University of Heidelberg, Mannheim, and Therapeutic Area Cardiovascular MedicineBoehringer Ingelheim International GmbHIngelheimGermany
| | - Patricia A. Peyser
- Department of Epidemiology, School of Public HealthUniversity of MichiganAnn Arbor
| | - Maryam Kavousi
- Department of Epidemiology, Erasmus MCUniversity Medical CenterRotterdamThe Netherlands
| | - Paul S. de Vries
- Human Genetics Center, Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public HealthThe University of Texas Health Science Center at Houston
| | - Clint L. Miller
- Center for Public Health Genomics, Department of Public Health SciencesUniversity of VirginiaCharlottesville
| | - Maxime Bos
- Department of Epidemiology, Erasmus MCUniversity Medical CenterRotterdamThe Netherlands
| | - Sander W. van der Laan
- Central Diagnostics Laboratory, Division of Laboratories, Pharmacy, and Biomedical Genetics, University Medical Center UtrechtUtrecht UniversityUtrechtthe Netherlands
| | - Rajeev Malhotra
- Cardiology Division, Department of MedicineMassachusetts General HospitalBoston
| | - Markus Herrmann
- Clinical Institute of Medical and Chemical Laboratory DiagnosticsMedical University of GrazGrazAustria
| | - Hubert Scharnagl
- Clinical Institute of Medical and Chemical Laboratory DiagnosticsMedical University of GrazGrazAustria
| | - Marcus Kleber
- SYNLAB Academy, SYNLAB Holding Deutschland GmbHMannheimGermany
| | - George Dedoussis
- Department of Nutrition and Dietetics, School of Health Science and EducationHarokopio UniversityAthensGreece
| | - Eleftheria Zeggini
- Institute of Translational Genomics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, and Technical University of Munich (TUM) and Klinikum Rechts der IsarTUM School of MedicineMunichGermany
| | - Maria Nethander
- Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg and Bioinformatics and Data Centre, Sahlgrenska AcademyUniversity of GothenburgGothenburgSweden
| | - Claes Ohlsson
- Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of MedicineUniversity of GothenburgGothenburgSweden
| | - Mattias Lorentzon
- Sahlgrenska Osteoporosis Centre, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, and Region Västra Götaland, Geriatric Medicine, Sahlgrenska University Hospital, Mölndal, Sweden, and Mary McKillop Institute for Health ResearchAustralian Catholic UniversityMelbourneVictoriaAustralia
| | - Nick Wareham
- MRC Epidemiology Unit, Institute of Metabolic ScienceUniversity of Cambridge School of Clinical MedicineCambridgeUK
| | - Claudia Langenberg
- MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK, and Computational Medicine, Berlin Institute of Health at Charité–Universitätsmedizin BerlinBerlinGermany
| | - Michael V. Holmes
- MRC IEU, Bristol Medical School, University of Bristol, and Medical Research Council Population Health Research Unit, University of Oxford, and Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population HealthUniversity of Oxford, and National Institute for Health Research, Oxford Biomedical Research Centre, Oxford University HospitalOxfordUK
| | | | - Jonathan H. Tobias
- MRC IEU, Bristol Medical School, University of Bristol, and Musculoskeletal Research UnitUniversity of BristolBristolUK
| |
Collapse
|
2
|
Medina-Gomez C, Mullin BH, Chesi A, Prijatelj V, Kemp JP, Shochat-Carvalho C, Trajanoska K, Wang C, Joro R, Evans TE, Schraut KE, Li-Gao R, Ahluwalia TS, Zillikens MC, Zhu K, Mook-Kanamori DO, Evans DS, Nethander M, Knol MJ, Thorleifsson G, Prokic I, Zemel B, Broer L, McGuigan FE, van Schoor NM, Reppe S, Pawlak MA, Ralston SH, van der Velde N, Lorentzon M, Stefansson K, Adams HHH, Wilson SG, Ikram MA, Walsh JP, Lakka TA, Gautvik KM, Wilson JF, Orwoll ES, van Duijn CM, Bønnelykke K, Uitterlinden AG, Styrkársdóttir U, Akesson KE, Spector TD, Tobias JH, Ohlsson C, Felix JF, Bisgaard H, Grant SFA, Richards JB, Evans DM, van der Eerden B, van de Peppel J, Ackert-Bicknell C, Karasik D, Kague E, Rivadeneira F. Bone mineral density loci specific to the skull portray potential pleiotropic effects on craniosynostosis. Commun Biol 2023; 6:691. [PMID: 37402774 PMCID: PMC10319806 DOI: 10.1038/s42003-023-04869-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2022] [Accepted: 04/25/2023] [Indexed: 07/06/2023] Open
Abstract
Skull bone mineral density (SK-BMD) provides a suitable trait for the discovery of key genes in bone biology, particularly to intramembranous ossification, not captured at other skeletal sites. We perform a genome-wide association meta-analysis (n ~ 43,800) of SK-BMD, identifying 59 loci, collectively explaining 12.5% of the trait variance. Association signals cluster within gene-sets involved in skeletal development and osteoporosis. Among the four novel loci (ZIC1, PRKAR1A, AZIN1/ATP6V1C1, GLRX3), there are factors implicated in intramembranous ossification and as we show, inherent to craniosynostosis processes. Functional follow-up in zebrafish confirms the importance of ZIC1 on cranial suture patterning. Likewise, we observe abnormal cranial bone initiation that culminates in ectopic sutures and reduced BMD in mosaic atp6v1c1 knockouts. Mosaic prkar1a knockouts present asymmetric bone growth and, conversely, elevated BMD. In light of this evidence linking SK-BMD loci to craniofacial abnormalities, our study provides new insight into the pathophysiology, diagnosis and treatment of skeletal diseases.
Collapse
Grants
- UL1 TR000128 NCATS NIH HHS
- U01 AG042124 NIA NIH HHS
- U01 AG042145 NIA NIH HHS
- U01 AG042168 NIA NIH HHS
- U01 AG042140 NIA NIH HHS
- U24 AG051129 NIA NIH HHS
- R01 AR051124 NIAMS NIH HHS
- U01 AG027810 NIA NIH HHS
- U01 AR066160 NIAMS NIH HHS
- MC_UU_00007/10 Medical Research Council
- R01 HD058886 NICHD NIH HHS
- RC2 AR058973 NIAMS NIH HHS
- Wellcome Trust
- M01 RR000240 NCRR NIH HHS
- U01 AG042143 NIA NIH HHS
- UL1 RR026314 NCRR NIH HHS
- U01 AG042139 NIA NIH HHS
- EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)
- European Cooperation in Science and Technology (COST)
- Wellcome Trust (Wellcome)
- Department of Health | National Health and Medical Research Council (NHMRC)
- U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- ZonMw (Netherlands Organisation for Health Research and Development)
- EC | EC Seventh Framework Programm | FP7 Ideas: European Research Council (FP7-IDEAS-ERC - Specific Programme: "Ideas" Implementing the Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities (2007 to 2013))
- Vetenskapsrådet (Swedish Research Council)
- U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research)
- NCHA (Netherlands Consortium Healthy Ageing) Leiden/ Rotterdam; Dutch Ministry of Economic Affairs, Agriculture and Innovation (project KB-15-004-003); the Research Institute for Diseases in the Elderly [Netherlands] (014-93-015; RIDE2)
- Clinical and Translational Research Center (5-MO1-RR-000240 and UL1 RR-026314); U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) GrantRecipient="Au50"
- European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947); Netherlands Organization for Scientific Research and the Russian Foundation for Basic Research (NWO-RFBR 047.017.043); Netherlands Brain Foundation (project number F2013(1)-28) GrantRecipient="Au40"
- Chief Scientist Office of the Scottish Government (CZB/4/276, CZB/4/710) GrantRecipient="Au28"
- Chief Scientist Office of the Scottish Government (CZB/4/276, CZB/4/710) GrantRecipient="Au38"
- The Pawsey Supercomputing Centre (with Funding from the Australian Government and the Government of Western Australia; PG 16/0162, PG 17/director2025) GrantRecipient="Au45”
- European Commission (EC)
- U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);NIH Roadmap for Medical Research [USA]: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128 GrantRecipient="Au39”
- Versus Arthritis [USA] 21937 GrantRecipient="Au57”
Collapse
Affiliation(s)
- Carolina Medina-Gomez
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
| | - Benjamin H Mullin
- Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA, 6009, Australia
- School of Biomedical Sciences, University of Western Australia, Nedlands, WA, 6009, Australia
| | - Alessandra Chesi
- Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA
| | - Vid Prijatelj
- Department of Oral and Maxillofacial Surgery, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
| | - John P Kemp
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, 4072, Australia
- The University of Queensland Diamantina Institute, The University of Queensland, Brisbane, QLD, 4102, Australia
- MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, BS8 2BN, UK
| | | | - Katerina Trajanoska
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
- Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
| | - Carol Wang
- School of Women's and Infants' Health, University of Western Australia, Crawley, WA, 6009, Australia
| | - Raimo Joro
- Institute of Biomedicine, Physiology, University of Eastern Finland, Kuopio, 70211, Finland
| | - Tavia E Evans
- Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
- Department of Radiology & Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
| | - Katharina E Schraut
- Centre for Global Health Research, Usher Institute, University of Edinburgh, Edinburgh, EH16 4UX, Scotland
- Centre for Cardiovascular Sciences, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, EH8 9AG, Scotland
| | - Ruifang Li-Gao
- Department of Clinical Epidemiology, Leiden University Medical Centre, 2333 ZA, Leiden, The Netherlands
| | - Tarunveer S Ahluwalia
- COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, 2820, Denmark
- Steno Diabetes Center Copenhagen, Herlev, 2820, Denmark
- The Bioinformatics Center, Department of Biology, University of Copenhagen, Copenhagen, 2200, Denmark
| | - M Carola Zillikens
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
| | - Kun Zhu
- Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA, 6009, Australia
- Medical School, University of Western Australia, Perth, WA, 6009, Australia
| | - Dennis O Mook-Kanamori
- Department of Clinical Epidemiology, Leiden University Medical Centre, 2333 ZA, Leiden, The Netherlands
- Department of Public Health and Primary Care, Leiden University Medical Centre, 2333 ZA, Leiden, The Netherlands
| | - Daniel S Evans
- California Pacific Medical Center Research Institute, San Francisco, CA, 94107, USA
| | - Maria Nethander
- Bioinformatics Core Facility, Sahlgrenska Academy, University of Gothenburg, 413 90, Gothenburg, Sweden
- Center for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 90, Gothenburg, Sweden
| | - Maria J Knol
- Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
| | | | - Ivana Prokic
- Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
| | - Babette Zemel
- Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
- Division of GI, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA
| | - Linda Broer
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
| | - Fiona E McGuigan
- Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences Malmö, Lund University, 205 02, Malmö, Sweden
| | - Natasja M van Schoor
- Department of Epidemiology and Data Science, Amsterdam UMC, 1081 HV, Amsterdam, The Netherlands
| | - Sjur Reppe
- Department of Plastic and Reconstructive Surgery, Oslo University Hospital, 0372, Oslo, Norway
- Department of Medical Biochemistry, Oslo University Hospital, 0372, Oslo, Norway
- Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, 0456, Oslo, Norway
| | - Mikolaj A Pawlak
- Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
- Department of Neurology, Poznan University of Medical Sciences, 61-701, Poznan, Poland
| | - Stuart H Ralston
- Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XU, Scotland
| | - Nathalie van der Velde
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
- Department of Geriatric Medicine, Amsterdam Public Health Research Institute, Amsterdam UMC, 1105 AZ, Amsterdam, The Netherlands
| | - Mattias Lorentzon
- Center for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 90, Gothenburg, Sweden
- Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, VIC, 3000, Australia
| | | | - Hieab H H Adams
- Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
- Department of Radiology & Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
- Latin American Brain Health (BrainLat), Universidad Adolfo Ibáñez, Santiago, Chile
| | - Scott G Wilson
- Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA, 6009, Australia
- School of Biomedical Sciences, University of Western Australia, Nedlands, WA, 6009, Australia
- Department of Twin Research & Genetic Epidemiology, King's College London, London, SE1 7EH, UK
| | - M Arfan Ikram
- Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
| | - John P Walsh
- Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA, 6009, Australia
- Medical School, University of Western Australia, Perth, WA, 6009, Australia
| | - Timo A Lakka
- Institute of Biomedicine, Physiology, University of Eastern Finland, Kuopio, 70211, Finland
- Kuopio Research Institute of Exercise Medicine, Kuopio, 70100, Finland
- Department of Clinical Physiology and Nuclear Medicine, University of Eastern Finland, Kuopio, 70210, Finland
| | - Kaare M Gautvik
- Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, 0456, Oslo, Norway
| | - James F Wilson
- Centre for Global Health Research, Usher Institute, University of Edinburgh, Edinburgh, EH16 4UX, Scotland
- MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XU, Scotland
| | - Eric S Orwoll
- Department of Public Health & Preventive Medicine, Oregon Health & Science University, Portland, OR, OR97239, USA
| | - Cornelia M van Duijn
- Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
| | - Klaus Bønnelykke
- COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, 2820, Denmark
| | - Andre G Uitterlinden
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
| | | | - Kristina E Akesson
- Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences Malmö, Lund University, 205 02, Malmö, Sweden
- Department of Orthopedics Malmö, Skåne University Hospital, S-21428, Malmö, Sweden
| | - Timothy D Spector
- Department of Twin Research & Genetic Epidemiology, King's College London, London, SE1 7EH, UK
| | - Jonathan H Tobias
- MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, BS8 2BN, UK
- Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, Bristol, BS10 5NB, UK
| | - Claes Ohlsson
- Center for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 90, Gothenburg, Sweden
- Department of Drug Treatment, Sahlgrenska University Hospital, Region Västra Götaland, SE-413 45, Gothenburg, Sweden
| | - Janine F Felix
- The Generation R Study Group, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
- Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
| | - Hans Bisgaard
- COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, 2820, Denmark
| | - Struan F A Grant
- Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA
- Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
- Division of Endocrinology, The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA
| | - J Brent Richards
- Department of Twin Research & Genetic Epidemiology, King's College London, London, SE1 7EH, UK
- Lady Davis Institute, Jewish General Hospital, Montreal, H3T 1E2, QC, Canada
| | - David M Evans
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, 4072, Australia
- The University of Queensland Diamantina Institute, The University of Queensland, Brisbane, QLD, 4102, Australia
- MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, BS8 2BN, UK
| | - Bram van der Eerden
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
| | - Jeroen van de Peppel
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands
| | | | - David Karasik
- Azrieli Faculty of Medicine, Bar-Ilan University, Safed, 1311502, Israel
- Marcus Institute for Aging Research, Hebrew SeniorLife, Roslindale, MA, 02131, USA
| | - Erika Kague
- The School of Physiology, Pharmacology and Neuroscience, Biomedical Sciences, University of Bristol, Bristol, BS8 1TD, UK
| | - Fernando Rivadeneira
- Department of Oral and Maxillofacial Surgery, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, The Netherlands.
| |
Collapse
|
3
|
Gautvik KM, Sachse D, Hinton AC, Olstad OK, Kiel DP, Hsu YH, Utheim TP, Lary CW, Reppe S. In silico discovery of blood cell macromolecular associations. BMC Genom Data 2022; 23:57. [PMID: 35879676 PMCID: PMC9317115 DOI: 10.1186/s12863-022-01077-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Accepted: 07/13/2022] [Indexed: 11/23/2022] Open
Abstract
Background Physical molecular interactions are the basis of intracellular signalling and gene regulatory networks, and comprehensive, accessible databases are needed for their discovery. Highly correlated transcripts may reflect important functional associations, but identification of such associations from primary data are cumbersome. We have constructed and adapted a user-friendly web application to discover and identify putative macromolecular associations in human peripheral blood based on significant correlations at the transcriptional level. Methods The blood transcriptome was characterized by quantification of 17,328 RNA species, including 341 mature microRNAs in 105 clinically well-characterized postmenopausal women. Intercorrelation of detected transcripts signal levels generated a matrix with > 150 million correlations recognizing the human blood RNA interactome. The correlations with calculated adjusted p-values were made easily accessible by a novel web application. Results We found that significant transcript correlations within the giant matrix reflect experimentally documented interactions involving select ubiquitous blood relevant transcription factors (CREB1, GATA1, and the glucocorticoid receptor (GR, NR3C1)). Their responsive genes recapitulated up to 91% of these as significant correlations, and were replicated in an independent cohort of 1204 individual blood samples from the Framingham Heart Study. Furthermore, experimentally documented mRNAs/miRNA associations were also reproduced in the matrix, and their predicted functional co-expression described. The blood transcript web application is available at http://app.uio.no/med/klinmed/correlation-browser/blood/index.php and works on all commonly used internet browsers. Conclusions Using in silico analyses and a novel web application, we found that correlated blood transcripts across 105 postmenopausal women reflected experimentally proven molecular associations. Furthermore, the associations were reproduced in a much larger and more heterogeneous cohort and should therefore be generally representative. The web application lends itself to be a useful hypothesis generating tool for identification of regulatory mechanisms in complex biological data sets. Supplementary Information The online version contains supplementary material available at 10.1186/s12863-022-01077-3.
Collapse
|
4
|
Gautvik KM, Olstad OK, Raue U, Gautvik VT, Kvernevik KJ, Utheim TP, Ravnum S, Kirkegaard C, Wiig H, Jones G, Pilling LC, Trappe S, Raastad T, Reppe S. Heavy-load exercise in older adults activates vasculogenesis and has a stronger impact on muscle gene expression than in young adults. Eur Rev Aging Phys Act 2022; 19:23. [PMID: 36182918 PMCID: PMC9526277 DOI: 10.1186/s11556-022-00304-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Accepted: 09/19/2022] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND A striking effect of old age is the involuntary loss of muscle mass and strength leading to sarcopenia and reduced physiological functions. However, effects of heavy-load exercise in older adults on diseases and functions as predicted by changes in muscle gene expression have been inadequately studied. METHODS Thigh muscle global transcriptional activity (transcriptome) was analyzed in cohorts of older and younger adults before and after 12-13 weeks heavy-load strength exercise using Affymetrix microarrays. Three age groups, similarly trained, were compared: younger adults (age 24 ± 4 years), older adults of average age 70 years (Oslo cohort) and above 80 years (old BSU cohort). To increase statistical strength, one of the older cohorts was used for validation. Ingenuity Pathway analysis (IPA) was used to identify predicted biological effects of a gene set that changed expression after exercise, and Principal Component Analysis (PCA) was used to visualize differences in muscle gene expressen between cohorts and individual participants as well as overall changes upon exercise. RESULTS Younger adults, showed few transcriptome changes, but a marked, significant impact was observed in persons of average age 70 years and even more so in persons above 80 years. The 249 transcripts positively or negatively altered in both cohorts of older adults (q-value < 0.1) were submitted to gene set enrichment analysis using IPA. The transcripts predicted increase in several aspects of "vascularization and muscle contractions", whereas functions associated with negative health effects were reduced, e.g., "Glucose metabolism disorder" and "Disorder of blood pressure". Several genes that changed expression after intervention were confirmed at the genome level by containing single nucleotide variants associated with handgrip strength and muscle expression levels, e.g., CYP4B1 (p = 9.2E-20), NOTCH4 (p = 9.7E-8), and FZD4 (p = 5.3E-7). PCA of the 249 genes indicated a differential pattern of muscle gene expression in young and elderly. However, after exercise the expression patterns in both young and old BSU cohorts were changed in the same direction for the vast majority of participants. CONCLUSIONS The positive impact of heavy-load strength training on the transcriptome increased markedly with age. The identified molecular changes translate to improved vascularization and muscular strength, suggesting highly beneficial health effects for older adults.
Collapse
Affiliation(s)
- Kaare M. Gautvik
- Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway
| | - Ole K. Olstad
- Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway
| | - Ulrika Raue
- Human Performance Lab, Ball State University, Muncie, IN USA
| | - Vigdis T. Gautvik
- Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway
| | - Karl J. Kvernevik
- Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway
| | - Tor P. Utheim
- Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway
- Department of Plastic and Reconstructive Surgery, Oslo University Hospital, Oslo, Norway
- Department of Ophthalmology, Stavanger University Hospital, Stavanger, Norway
- Department of Ophthalmology, Sørlandet Hospital Arendal Surgical Unit, Arendal, Norway
| | - Solveig Ravnum
- Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway
| | - Camilla Kirkegaard
- Department of Physical Performance, Norwegian School of Sports Sciences, Oslo, Norway
| | - Håvard Wiig
- Department of Physical Performance, Norwegian School of Sports Sciences, Oslo, Norway
| | - Garan Jones
- College of Medicine and Health, University of Exeter, Exeter, UK
| | - Luke C. Pilling
- College of Medicine and Health, University of Exeter, Exeter, UK
| | - Scott Trappe
- Human Performance Lab, Ball State University, Muncie, IN USA
| | - Truls Raastad
- Department of Physical Performance, Norwegian School of Sports Sciences, Oslo, Norway
| | - Sjur Reppe
- Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway
- Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway
- Department of Plastic and Reconstructive Surgery, Oslo University Hospital, Oslo, Norway
| |
Collapse
|
5
|
Datta HK, Kringen MK, Tuck SP, Salpingidou G, Olstad OK, Gautvik KM, Cockell SJ, Gautvik VT, Prediger M, Wu JJ, Birch MA, Reppe S. Mechanical-Stress-Related Epigenetic Regulation of ZIC1 Transcription Factor in the Etiology of Postmenopausal Osteoporosis. Int J Mol Sci 2022; 23:ijms23062957. [PMID: 35328378 PMCID: PMC8955993 DOI: 10.3390/ijms23062957] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Revised: 03/02/2022] [Accepted: 03/05/2022] [Indexed: 12/21/2022] Open
Abstract
Mechanical loading exerts a profound influence on bone density and architecture, but the exact mechanism is unknown. Our study shows that expression of the neurological transcriptional factor zinc finger of the cerebellum 1 (ZIC1) is markedly increased in trabecular bone biopsies in the lumbar spine compared with the iliac crest, skeletal sites of high and low mechanical stress, respectively. Human trabecular bone transcriptome analyses revealed a strong association between ZIC1 mRNA levels and gene transcripts characteristically associated with osteoblasts, osteocytes and osteoclasts. This supposition is supported by higher ZIC1 expression in iliac bone biopsies from postmenopausal women with osteoporosis compared with age-matched control subjects, as well as strongly significant inverse correlation between ZIC1 mRNA levels and BMI-adjusted bone mineral density (BMD) (Z-score). ZIC1 promoter methylation was decreased in mechanically loaded vertebral bone compared to unloaded normal iliac bone, and its mRNA levels correlated inversely with ZIC1 promoter methylation, thus linking mechanical stress to epigenetic control of gene expression. The findings were corroborated in cultures of rat osteoblast progenitors and osteoblast-like cells. This study demonstrates for the first time how skeletal epigenetic changes that are affected by mechanical forces give rise to marked alteration in bone cell transcriptional activity and translate to human bone pathophysiology.
Collapse
Affiliation(s)
- Harish K. Datta
- Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK; (S.P.T.); (M.A.B.)
- Blood Sciences, South Tees Hospitals NHS Foundation Trust, Middlesbrough TS4 3BW, UK
- Correspondence: ; Tel.: +44-01642-854161
| | | | - Stephen P. Tuck
- Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK; (S.P.T.); (M.A.B.)
| | - Georgia Salpingidou
- Department of Engineering, Faculty of Science, Durham University, Durham DH1 3 LE, UK; (G.S.); (J.J.W.)
| | - Ole K. Olstad
- Department of Medical Biochemistry, Oslo University Hospital, 0424 Oslo, Norway; (O.K.O.); (S.R.)
| | - Kaare M. Gautvik
- Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, 0440 Oslo, Norway; (K.M.G.); (V.T.G.)
| | - Simon J. Cockell
- School of Biomedical, Nutritional and Sport Sciences, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK;
| | - Vigdis T. Gautvik
- Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, 0440 Oslo, Norway; (K.M.G.); (V.T.G.)
| | - Michael Prediger
- Blood Sciences, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary, Newcastle upon Tyne NE2 4HH, UK;
| | - Jun Jie Wu
- Department of Engineering, Faculty of Science, Durham University, Durham DH1 3 LE, UK; (G.S.); (J.J.W.)
| | - Mark A. Birch
- Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK; (S.P.T.); (M.A.B.)
| | - Sjur Reppe
- Department of Medical Biochemistry, Oslo University Hospital, 0424 Oslo, Norway; (O.K.O.); (S.R.)
- Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, 0440 Oslo, Norway; (K.M.G.); (V.T.G.)
- Department of Plastic and Reconstructive Surgery, Oslo University Hospital, 0424 Oslo, Norway
| |
Collapse
|
6
|
Gautvik KM, Günther CC, Prijatelj V, Medina-Gomez C, Shevroja E, Rad LH, Yazdani M, Lindalen E, Valland H, Gautvik VT, Olstad OK, Holden M, Rivadeneira F, Utheim TP, Reppe S. Distinct Subsets of Noncoding RNAs Are Strongly Associated With BMD and Fracture, Studied in Weight-Bearing and Non-Weight-Bearing Human Bone. J Bone Miner Res 2020; 35:1065-1076. [PMID: 32017184 DOI: 10.1002/jbmr.3974] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2019] [Revised: 01/22/2020] [Accepted: 01/26/2020] [Indexed: 12/14/2022]
Abstract
We investigated mechanisms resulting in low bone mineral density (BMD) and susceptibility to fracture by comparing noncoding RNAs (ncRNAs) in biopsies of non-weight-bearing (NWB) iliac (n = 84) and weight bearing (WB) femoral (n = 18) postmenopausal bone across BMDs varying from normal (T-score > -1.0) to osteoporotic (T-score ≤ -2.5). Global bone ncRNA concentrations were determined by PCR and microchip analyses. Association with BMD or fracture, adjusted by age and body mass index, were calculated using linear and logistic regression and least absolute shrinkage and selection operator (Lasso) analysis. At 10% false discovery rate (FDR), 75 iliac bone ncRNAs and 94 femoral bone ncRNAs were associated with total hip BMD. Eight of the ncRNAs were common for the two sites, but five of them (miR-484, miR-328-3p, miR-27a-5p, miR-28-3p, and miR-409-3p) correlated positively to BMD in femoral bone, but negatively in iliac bone. Of predicted pathways recognized in bone metabolism, ECM-receptor interaction and proteoglycans in cancer emerged at both sites, whereas fatty acid metabolism and focal adhesion were only identified in iliac bone. Lasso analysis and cross-validations identified sets of nine bone ncRNAs correlating strongly with adjusted total hip BMD in both femoral and iliac bone. Twenty-eight iliac ncRNAs were associated with risk of fracture (FDR < 0.1). The small nucleolar RNAs, RNU44 and RNU48, have a function in stabilization of ribosomal RNAs (rRNAs), and their association with fracture and BMD suggest that aberrant processing of rRNAs may be involved in development of osteoporosis. Cis-eQTL (expressed quantitative trait loci) analysis of the iliac bone biopsies identified two loci associated with microRNAs (miRNAs), one previously identified in a heel-BMD genomewide association study (GWAS). In this comprehensive investigation of the skeletal genetic background in postmenopausal women, we identified functional bone ncRNAs associated to fracture and BMD, representing distinct subsets in WB and NWB skeletal sites. © 2020 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.
Collapse
Affiliation(s)
- Kaare M Gautvik
- Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway.,Department of Molecular Medicine, University of Oslo, Oslo, Norway
| | | | - Vid Prijatelj
- Department of Maxillofacial Surgery, Special Dental Care and Orthodontics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.,Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
| | - Carolina Medina-Gomez
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
| | - Enisa Shevroja
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
| | - Leila Heidary Rad
- Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway
| | - Mazyar Yazdani
- Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway
| | - Einar Lindalen
- Orthopaedic Department, Lovisenberg Diaconal Hospital, Oslo, Norway
| | - Haldor Valland
- Department of Surgery, Diakonhjemmet Hospital, Oslo, Norway
| | - Vigdis T Gautvik
- Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway
| | - Ole K Olstad
- Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway
| | | | - Fernando Rivadeneira
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
| | - Tor P Utheim
- Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.,Department of Plastic and Reconstructive Surgery, Oslo University Hospital, Oslo, Norway.,Department of Ophthalmology, Stavanger University Hospital, Oslo, Norway.,Department of Ophthalmology, Sørlandet Hospital, Arendal, Norway
| | - Sjur Reppe
- Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway.,Department of Molecular Medicine, University of Oslo, Oslo, Norway.,Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.,Department of Plastic and Reconstructive Surgery, Oslo University Hospital, Oslo, Norway
| |
Collapse
|
7
|
Zheng J, Maerz W, Gergei I, Kleber M, Drechsler C, Wanner C, Brandenburg V, Reppe S, Gautvik KM, Medina-Gomez C, Shevroja E, Gilly A, Park YC, Dedoussis G, Zeggini E, Lorentzon M, Henning P, Lerner UH, Nilsson KH, Movérare-Skrtic S, Baird D, Elsworth B, Falk L, Groom A, Capellini TD, Grundberg E, Nethander M, Ohlsson C, Davey Smith G, Tobias JH. Mendelian Randomization Analysis Reveals a Causal Influence of Circulating Sclerostin Levels on Bone Mineral Density and Fractures. J Bone Miner Res 2019; 34:1824-1836. [PMID: 31170332 PMCID: PMC6899787 DOI: 10.1002/jbmr.3803] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2018] [Revised: 05/14/2019] [Accepted: 05/23/2019] [Indexed: 12/21/2022]
Abstract
In bone, sclerostin is mainly osteocyte-derived and plays an important local role in adaptive responses to mechanical loading. Whether circulating levels of sclerostin also play a functional role is currently unclear, which we aimed to examine by two-sample Mendelian randomization (MR). A genetic instrument for circulating sclerostin, derived from a genomewide association study (GWAS) meta-analysis of serum sclerostin in 10,584 European-descent individuals, was examined in relation to femoral neck bone mineral density (BMD; n = 32,744) in GEFOS and estimated bone mineral density (eBMD) by heel ultrasound (n = 426,824) and fracture risk (n = 426,795) in UK Biobank. Our GWAS identified two novel serum sclerostin loci, B4GALNT3 (standard deviation [SD]) change in sclerostin per A allele (β = 0.20, p = 4.6 × 10-49 ) and GALNT1 (β = 0.11 per G allele, p = 4.4 × 10-11 ). B4GALNT3 is an N-acetyl-galactosaminyltransferase, adding a terminal LacdiNAc disaccharide to target glycocoproteins, found to be predominantly expressed in kidney, whereas GALNT1 is an enzyme causing mucin-type O-linked glycosylation. Using these two single-nucleotide polymorphisms (SNPs) as genetic instruments, MR revealed an inverse causal relationship between serum sclerostin and femoral neck BMD (β = -0.12, 95% confidence interval [CI] -0.20 to -0.05) and eBMD (β = -0.12, 95% CI -0.14 to -0.10), and a positive relationship with fracture risk (β = 0.11, 95% CI 0.01 to 0.21). Colocalization analysis demonstrated common genetic signals within the B4GALNT3 locus for higher sclerostin, lower eBMD, and greater B4GALNT3 expression in arterial tissue (probability >99%). Our findings suggest that higher sclerostin levels are causally related to lower BMD and greater fracture risk. Hence, strategies for reducing circulating sclerostin, for example by targeting glycosylation enzymes as suggested by our GWAS results, may prove valuable in treating osteoporosis. © 2019 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Jie Zheng
- MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Bristol, UK
| | - Winfried Maerz
- Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.,SYNLAB Academy, SYNLAB Holding Deutschland GmbH, Mannheim, Germany.,Vth Department of Medicine (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Diabetology), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Ingrid Gergei
- Vth Department of Medicine (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Diabetology), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Marcus Kleber
- Vth Department of Medicine (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Diabetology), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | | | - Christoph Wanner
- Department of Cardiology and Nephrology, Rhein-Maas-Klinikum Würselen, Germany
| | - Vincent Brandenburg
- Department of Cardiology and Nephrology, Rhein-Maas-Klinikum Würselen, Germany
| | - Sjur Reppe
- Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.,Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway
| | - Kaare M Gautvik
- Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway.,Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
| | - Carolina Medina-Gomez
- Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands
| | - Enisa Shevroja
- Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands
| | - Arthur Gilly
- Human Genetics, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.,Institute of Translational Genomics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
| | - Young-Chan Park
- Human Genetics, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.,University of Cambridge, Cambridge, UK
| | - George Dedoussis
- Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece
| | - Eleftheria Zeggini
- Human Genetics, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.,Institute of Translational Genomics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
| | - Mattias Lorentzon
- Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.,Geriatric Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.,Geriatric Medicine Clinic, Sahlgrenska University Hospital, Mölndal, Sweden
| | - Petra Henning
- Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
| | - Ulf H Lerner
- Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
| | - Karin H Nilsson
- Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
| | - Sofia Movérare-Skrtic
- Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
| | - Denis Baird
- MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Bristol, UK
| | - Benjamin Elsworth
- MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Bristol, UK
| | - Louise Falk
- MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Bristol, UK
| | - Alix Groom
- MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Bristol, UK.,Bristol Bioresource Laboratories, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Terence D Capellini
- Human Evolutionary Biology, Harvard University, Boston, MA, USA.,Broad Institute of MIT and Harvard, Boston, MA, USA
| | - Elin Grundberg
- Department of Human Genetics, McGill University, Quebec, Canada.,Center for Pediatric Genomic Medicine, Children's Mercy, Kansas City, MO, USA
| | - Maria Nethander
- Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
| | - Claes Ohlsson
- Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
| | - George Davey Smith
- MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Bristol, UK
| | - Jonathan H Tobias
- MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Bristol, UK.,Musculoskeletal Research Unit, University of Bristol, Bristol, UK
| |
Collapse
|
8
|
Alonso N, Estrada K, Albagha OME, Herrera L, Reppe S, Olstad OK, Gautvik KM, Ryan NM, Evans KL, Nielson CM, Hsu YH, Kiel DP, Markozannes G, Ntzani EE, Evangelou E, Feenstra B, Liu X, Melbye M, Masi L, Brandi ML, Riches P, Daroszewska A, Olmos JM, Valero C, Castillo J, Riancho JA, Husted LB, Langdahl BL, Brown MA, Duncan EL, Kaptoge S, Khaw KT, Usategui-Martín R, Del Pino-Montes J, González-Sarmiento R, Lewis JR, Prince RL, D’Amelio P, García-Giralt N, NoguéS X, Mencej-Bedrac S, Marc J, Wolstein O, Eisman JA, Oei L, Medina-Gómez C, Schraut KE, Navarro P, Wilson JF, Davies G, Starr J, Deary I, Tanaka T, Ferrucci L, Gianfrancesco F, Gennari L, Lucas G, Elosua R, Uitterlinden AG, Rivadeneira F, Ralston SH. Identification of a novel locus on chromosome 2q13, which predisposes to clinical vertebral fractures independently of bone density. Ann Rheum Dis 2018; 77:378-385. [PMID: 29170203 PMCID: PMC5912156 DOI: 10.1136/annrheumdis-2017-212469] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2017] [Accepted: 11/01/2017] [Indexed: 12/20/2022]
Abstract
OBJECTIVES To identify genetic determinants of susceptibility to clinical vertebral fractures, which is an important complication of osteoporosis. METHODS Here we conduct a genome-wide association study in 1553 postmenopausal women with clinical vertebral fractures and 4340 controls, with a two-stage replication involving 1028 cases and 3762 controls. Potentially causal variants were identified using expression quantitative trait loci (eQTL) data from transiliac bone biopsies and bioinformatic studies. RESULTS A locus tagged by rs10190845 was identified on chromosome 2q13, which was significantly associated with clinical vertebral fracture (P=1.04×10-9) with a large effect size (OR 1.74, 95% CI 1.06 to 2.6). Bioinformatic analysis of this locus identified several potentially functional SNPs that are associated with expression of the positional candidate genes TTL (tubulin tyrosine ligase) and SLC20A1 (solute carrier family 20 member 1). Three other suggestive loci were identified on chromosomes 1p31, 11q12 and 15q11. All these loci were novel and had not previously been associated with bone mineral density or clinical fractures. CONCLUSION We have identified a novel genetic variant that is associated with clinical vertebral fractures by mechanisms that are independent of BMD. Further studies are now in progress to validate this association and evaluate the underlying mechanism.
Collapse
Affiliation(s)
- Nerea Alonso
- Rheumatology and Bone disease Unit, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - Karol Estrada
- Departments of Internal Medicine and Epidemiology, Erasmus Medical Centre, Rotterdam, The Netherlands
| | - Omar M E Albagha
- Rheumatology and Bone disease Unit, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
- Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Doha, Qatar
| | - Lizbeth Herrera
- Departments of Internal Medicine and Epidemiology, Erasmus Medical Centre, Rotterdam, The Netherlands
| | - Sjur Reppe
- Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway
- Department of Clinical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway
- Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
| | - Ole K Olstad
- Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway
| | - Kaare M Gautvik
- Department of Clinical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway
- Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
| | - Niamh M Ryan
- Centre for Genomic and Experimental Medicine, IGMM, University of Edinburgh, Edinburgh, UK
| | - Kathryn L Evans
- Centre for Genomic and Experimental Medicine, IGMM, University of Edinburgh, Edinburgh, UK
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK
| | - Carrie M Nielson
- Department of Public Health and Preventive Medicine, Oregon Health and Science University, Portland, Oregon, USA
| | - Yi-Hsiang Hsu
- Department of Medicine Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
- BROAD Institute of MIT and Harvard, Cambridge, Massachusetts, USA
- Musculoskeletal Research Center, Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts, USA
| | - Douglas P Kiel
- BROAD Institute of MIT and Harvard, Cambridge, Massachusetts, USA
- Musculoskeletal Research Center, Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts, USA
- Harvard Medical School, Boston, Massachusetts, USA
| | - George Markozannes
- Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece
| | - Evangelia E Ntzani
- Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece
- Centre for Evidence Synthesis in Health, Department of Health Services, Policy and Practice, School of Public Health, Brown University, Rhode Island, USA
| | - Evangelos Evangelou
- Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece
- Department of Epidemiology and Biostatistics, Imperial College London, London, UK
| | - Bjarke Feenstra
- Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
| | - Xueping Liu
- Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
| | - Mads Melbye
- Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Department of Medicine, Stanford School of Medicine, Stanford, California, USA
| | - Laura Masi
- Department of Surgery and Translational Medicine, University of Florence, Florence, Italy
| | - Maria Luisa Brandi
- Department of Surgery and Translational Medicine, University of Florence, Florence, Italy
| | - Philip Riches
- Rheumatology and Bone disease Unit, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - Anna Daroszewska
- Rheumatology and Bone disease Unit, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
- Institute of Ageing and Chronic Disease, The MRC-Arthritis Research UK Centre for Integrated Research into Musculoskeletal Ageing, University of Liverpool, Liverpool, UK
| | - José Manuel Olmos
- Department of Internal Medicine, Hospital UM Valdecilla, University of Cantabria, IDIVAL, RETICEF, Santander, Spain
| | - Carmen Valero
- Department of Internal Medicine, Hospital UM Valdecilla, University of Cantabria, IDIVAL, RETICEF, Santander, Spain
| | - Jesús Castillo
- Department of Internal Medicine, Hospital UM Valdecilla, University of Cantabria, IDIVAL, RETICEF, Santander, Spain
| | - José A Riancho
- Department of Internal Medicine, Hospital UM Valdecilla, University of Cantabria, IDIVAL, RETICEF, Santander, Spain
| | - Lise B Husted
- Department of Endocrinology and Internal Medicine THG, Aarhus University Hospital, Aarhus, Denmark
| | - Bente L Langdahl
- Department of Endocrinology and Internal Medicine THG, Aarhus University Hospital, Aarhus, Denmark
| | - Matthew A Brown
- Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Queensland, Australia
| | - Emma L Duncan
- Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Queensland, Australia
- Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia
- Department of Endocrinology, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia
| | - Stephen Kaptoge
- Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Kay-Tee Khaw
- Department of Public Health and Primary Care, School of Medicine, University of Cambridge, Cambridge, UK
| | - Ricardo Usategui-Martín
- Molecular Medicine Unit, Department of Medicine and Biomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca, University of Salamanca – CSIC, Salamanca, Spain
| | - Javier Del Pino-Montes
- Molecular Medicine Unit, Department of Medicine and Biomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca, University of Salamanca – CSIC, Salamanca, Spain
| | - Rogelio González-Sarmiento
- Molecular Medicine Unit, Department of Medicine and Biomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca, University of Salamanca – CSIC, Salamanca, Spain
| | - Joshua R Lewis
- School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia
- Centre for Kidney Research, School of Public Health, University of Sydney, Sydney, New South Wales, Australia
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
| | - Richard L Prince
- School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia
- Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
| | - Patrizia D’Amelio
- Gerontology and Bone Metabolic Diseases Unit, Department of Medical Science, University of Torino, Torino, Italy
| | - Natalia García-Giralt
- Department of Internal Medicine, Hospital del Mar-IMIM, RETICEF, Universitat Autonoma de Barcelona, Barcelona, Spain
| | - Xavier NoguéS
- Department of Internal Medicine, Hospital del Mar-IMIM, RETICEF, Universitat Autonoma de Barcelona, Barcelona, Spain
| | - Simona Mencej-Bedrac
- Department of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
| | - Janja Marc
- Department of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
| | - Orit Wolstein
- Osteoporosis and Bone Biology Program, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
| | - John A Eisman
- Osteoporosis and Bone Biology Program, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
| | - Ling Oei
- Departments of Internal Medicine and Epidemiology, Erasmus Medical Centre, Rotterdam, The Netherlands
| | - Carolina Medina-Gómez
- Departments of Internal Medicine and Epidemiology, Erasmus Medical Centre, Rotterdam, The Netherlands
| | - Katharina E Schraut
- Centre for Global Health Research, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
- Edinburgh/British Heart Foundation Centre for Cardiovascular Science, QMRI, University of Edinburgh, Edinburgh, UK
| | - Pau Navarro
- MRC Human Genetics Unit, MRC, IGMM, University of Edinburgh, Edinburgh, UK
| | - James F Wilson
- Centre for Global Health Research, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
- MRC Human Genetics Unit, MRC, IGMM, University of Edinburgh, Edinburgh, UK
| | - Gail Davies
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK
| | - John Starr
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK
| | - Ian Deary
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK
| | - Toshiko Tanaka
- Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, Maryland, USA
| | - Luigi Ferrucci
- Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, Maryland, USA
| | - Fernando Gianfrancesco
- Institute of Genetics and Biophysics "Adriano Buzzati-Traverso", National Research Council of Italy, Naples, Italy
| | - Luigi Gennari
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - Gavin Lucas
- Grup de Recerca en Genètica i Epidemiologia Cardiovascular, IMIM, Barcelona, Spain
| | - Roberto Elosua
- Grup de Recerca en Genètica i Epidemiologia Cardiovascular, IMIM, Barcelona, Spain
| | - André G Uitterlinden
- Departments of Internal Medicine and Epidemiology, Erasmus Medical Centre, Rotterdam, The Netherlands
| | - Fernando Rivadeneira
- Departments of Internal Medicine and Epidemiology, Erasmus Medical Centre, Rotterdam, The Netherlands
| | - Stuart H Ralston
- Rheumatology and Bone disease Unit, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
9
|
Reppe S, Datta HK, Gautvik KM. Omics analysis of human bone to identify genes and molecular networks regulating skeletal remodeling in health and disease. Bone 2017; 101:88-95. [PMID: 28450214 DOI: 10.1016/j.bone.2017.04.012] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2016] [Revised: 04/13/2017] [Accepted: 04/22/2017] [Indexed: 12/11/2022]
Abstract
The skeleton is a metabolically active organ throughout life where specific bone cell activity and paracrine/endocrine factors regulate its morphogenesis and remodeling. In recent years, an increasing number of reports have used multi-omics technologies to characterize subsets of bone biological molecular networks. The skeleton is affected by primary and secondary disease, lifestyle and many drugs. Therefore, to obtain relevant and reliable data from well characterized patient and control cohorts are vital. Here we provide a brief overview of omics studies performed on human bone, of which our own studies performed on trans-iliacal bone biopsies from postmenopausal women with osteoporosis (OP) and healthy controls are among the first and largest. Most other studies have been performed on smaller groups of patients, undergoing hip replacement for osteoarthritis (OA) or fracture, and without healthy controls. The major findings emerging from the combined studies are: 1. Unstressed and stressed bone show profoundly different gene expression reflecting differences in bone turnover and remodeling and 2. Omics analyses comparing healthy/OP and control/OA cohorts reveal characteristic changes in transcriptomics, epigenomics (DNA methylation), proteomics and metabolomics. These studies, together with genome-wide association studies, in vitro observations and transgenic animal models have identified a number of genes and gene products that act via Wnt and other signaling systems and are highly associated to bone density and fracture. Future challenge is to understand the functional interactions between bone-related molecular networks and their significance in OP and OA pathogenesis, and also how the genomic architecture is affected in health and disease.
Collapse
Affiliation(s)
- Sjur Reppe
- Oslo University Hospital, Department of Medical Biochemistry, Oslo, Norway; Lovisenberg Diakonale Hospital, Unger-Vetlesen Institute, Oslo, Norway.
| | - Harish K Datta
- Pathology Department, Biochemistry Section, James Cook University Hospital, Middlesbrough, UK; Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
| | - Kaare M Gautvik
- Lovisenberg Diakonale Hospital, Unger-Vetlesen Institute, Oslo, Norway; University of Oslo, Institute of Basic Medical Sciences, Oslo, Norway
| |
Collapse
|
10
|
Reppe S, Lien TG, Hsu YH, Gautvik VT, Olstad OK, Yu R, Bakke HG, Lyle R, Kringen MK, Glad IK, Gautvik KM. Distinct DNA methylation profiles in bone and blood of osteoporotic and healthy postmenopausal women. Epigenetics 2017. [PMID: 28650214 DOI: 10.1080/15592294.2017.1345832] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
DNA methylation affects expression of associated genes and may contribute to the missing genetic effects from genome-wide association studies of osteoporosis. To improve insight into the mechanisms of postmenopausal osteoporosis, we combined transcript profiling with DNA methylation analyses in bone. RNA and DNA were isolated from 84 bone biopsies of postmenopausal donors varying markedly in bone mineral density (BMD). In all, 2529 CpGs in the top 100 genes most significantly associated with BMD were analyzed. The methylation levels at 63 CpGs differed significantly between healthy and osteoporotic women at 10% false discovery rate (FDR). Five of these CpGs at 5% FDR could explain 14% of BMD variation. To test whether blood DNA methylation reflect the situation in bone (as shown for other tissues), an independent cohort was selected and BMD association was demonstrated in blood for 13 of the 63 CpGs. Four transcripts representing inhibitors of bone metabolism-MEPE, SOST, WIF1, and DKK1-showed correlation to a high number of methylated CpGs, at 5% FDR. Our results link DNA methylation to the genetic influence modifying the skeleton, and the data suggest a complex interaction between CpG methylation and gene regulation. This is the first study in the hitherto largest number of postmenopausal women to demonstrate a strong association among bone CpG methylation, transcript levels, and BMD/fracture. This new insight may have implications for evaluation of osteoporosis stage and susceptibility.
Collapse
Affiliation(s)
- Sjur Reppe
- a Department of Medical Biochemistry , Oslo University Hospital , Oslo , Norway.,b Lovisenberg Diakonale Hospital, Unger-Vetlesen Institute , Oslo , Norway.,c University of Oslo, Institute of Basic Medical Sciences , Oslo , Norway
| | - Tonje G Lien
- d Department of Mathematics , University of Oslo , Oslo , Norway
| | - Yi-Hsiang Hsu
- e Hebrew SeniorLife Institute for Aging Research and Harvard Medical School , Boston , MA , USA.,f Broad Institute of MIT and Harvard , Cambridge , MA , USA.,g Molecular and Physiological Sciences Program, Harvard School of Public Health , Boston , MA , USA.,h Gerontology Division , Department of Medicine , Beth Israel Deaconess Medical Center , Boston , MA , USA
| | - Vigdis T Gautvik
- c University of Oslo, Institute of Basic Medical Sciences , Oslo , Norway
| | - Ole K Olstad
- a Department of Medical Biochemistry , Oslo University Hospital , Oslo , Norway
| | - Rona Yu
- e Hebrew SeniorLife Institute for Aging Research and Harvard Medical School , Boston , MA , USA
| | - Hege G Bakke
- i Center for Psychopharmacology, Diakonhjemmet Hospital , Oslo , Norway
| | - Robert Lyle
- j Department of Medical Genetics , Oslo University Hospital , Oslo , Norway.,k Department of Medical Genetics , University of Oslo , Oslo , Norway
| | | | - Ingrid K Glad
- d Department of Mathematics , University of Oslo , Oslo , Norway
| | - Kaare M Gautvik
- b Lovisenberg Diakonale Hospital, Unger-Vetlesen Institute , Oslo , Norway.,c University of Oslo, Institute of Basic Medical Sciences , Oslo , Norway
| |
Collapse
|
11
|
Nielson CM, Liu CT, Smith AV, Ackert-Bicknell CL, Reppe S, Jakobsdottir J, Wassel C, Register TC, Oei L, Alonso N, Oei EH, Parimi N, Samelson EJ, Nalls MA, Zmuda J, Lang T, Bouxsein M, Latourelle J, Claussnitzer M, Siggeirsdottir K, Srikanth P, Lorentzen E, Vandenput L, Langefeld C, Raffield L, Terry G, Cox AJ, Allison MA, Criqui MH, Bowden D, Ikram MA, Mellström D, Karlsson MK, Carr J, Budoff M, Phillips C, Cupples LA, Chou WC, Myers RH, Ralston SH, Gautvik KM, Cawthon PM, Cummings S, Karasik D, Rivadeneira F, Gudnason V, Orwoll ES, Harris TB, Ohlsson C, Kiel DP, Hsu YH. Novel Genetic Variants Associated With Increased Vertebral Volumetric BMD, Reduced Vertebral Fracture Risk, and Increased Expression of SLC1A3 and EPHB2. J Bone Miner Res 2016; 31:2085-2097. [PMID: 27476799 PMCID: PMC5477772 DOI: 10.1002/jbmr.2913] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2016] [Revised: 06/22/2016] [Accepted: 07/08/2016] [Indexed: 12/26/2022]
Abstract
Genome-wide association studies (GWASs) have revealed numerous loci for areal bone mineral density (aBMD). We completed the first GWAS meta-analysis (n = 15,275) of lumbar spine volumetric BMD (vBMD) measured by quantitative computed tomography (QCT), allowing for examination of the trabecular bone compartment. SNPs that were significantly associated with vBMD were also examined in two GWAS meta-analyses to determine associations with morphometric vertebral fracture (n = 21,701) and clinical vertebral fracture (n = 5893). Expression quantitative trait locus (eQTL) analyses of iliac crest biopsies were performed in 84 postmenopausal women, and murine osteoblast expression of genes implicated by eQTL or by proximity to vBMD-associated SNPs was examined. We identified significant vBMD associations with five loci, including: 1p36.12, containing WNT4 and ZBTB40; 8q24, containing TNFRSF11B; and 13q14, containing AKAP11 and TNFSF11. Two loci (5p13 and 1p36.12) also contained associations with radiographic and clinical vertebral fracture, respectively. In 5p13, rs2468531 (minor allele frequency [MAF] = 3%) was associated with higher vBMD (β = 0.22, p = 1.9 × 10-8 ) and decreased risk of radiographic vertebral fracture (odds ratio [OR] = 0.75; false discovery rate [FDR] p = 0.01). In 1p36.12, rs12742784 (MAF = 21%) was associated with higher vBMD (β = 0.09, p = 1.2 × 10-10 ) and decreased risk of clinical vertebral fracture (OR = 0.82; FDR p = 7.4 × 10-4 ). Both SNPs are noncoding and were associated with increased mRNA expression levels in human bone biopsies: rs2468531 with SLC1A3 (β = 0.28, FDR p = 0.01, involved in glutamate signaling and osteogenic response to mechanical loading) and rs12742784 with EPHB2 (β = 0.12, FDR p = 1.7 × 10-3 , functions in bone-related ephrin signaling). Both genes are expressed in murine osteoblasts. This is the first study to link SLC1A3 and EPHB2 to clinically relevant vertebral osteoporosis phenotypes. These results may help elucidate vertebral bone biology and novel approaches to reducing vertebral fracture incidence. © 2016 American Society for Bone and Mineral Research.
Collapse
Affiliation(s)
- Carrie M Nielson
- School of Public Health, Oregon Health & Science University, Portland, OR, USA
| | - Ching-Ti Liu
- Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
| | - Albert V Smith
- Icelandic Heart Association, Kópavogur, Iceland.,Faculty of Medicine, University of Iceland, Reykjavík, Iceland
| | | | - Sjur Reppe
- Department of Medical Biochemistry, Oslo University Hospital, Ullevål, Oslo, Norway.,Lovisenberg Diakonale Hospital, Oslo, Norway.,Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
| | | | - Christina Wassel
- Department of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington, VT, USA
| | - Thomas C Register
- Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Ling Oei
- Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.,Netherlands Genomics Initiative (NGI)-sponsored Netherlands Consortium for Healthy Aging (NCHA), Leiden, The Netherlands
| | - Nerea Alonso
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland, UK
| | - Edwin H Oei
- Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
| | - Neeta Parimi
- California Pacific Medical Center Research Institute, San Francisco, CA, USA
| | - Elizabeth J Samelson
- Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, MA, USA
| | - Mike A Nalls
- National Institute on Aging (NIA), National Institutes of Health, Bethesda, MD, USA
| | - Joseph Zmuda
- Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA
| | - Thomas Lang
- Department of Radiology, University of California, San Francisco (UCSF) School of Medicine, San Francisco, CA, USA
| | - Mary Bouxsein
- Center for Advanced Orthopedic Studies, Beth Israel Deaconess Medical Center, Harvard University Medical School, Boston, MA, USA
| | | | - Melina Claussnitzer
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University Medical School, Boston, MA, USA.,Broad Institute of MIT and Harvard, Cambridge, MA, USA.,Technical University Munich, Munich, Germany
| | | | - Priya Srikanth
- School of Public Health, Oregon Health & Science University, Portland, OR, USA
| | - Erik Lorentzen
- Department of Bioinformatics, Gothenburg University, Gothenburg, Sweden
| | - Liesbeth Vandenput
- Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Carl Langefeld
- Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Laura Raffield
- Center for Human Genomics, Wake Forest School of Medicine, Winston-Salem, NC, USA.,Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Greg Terry
- Department of Radiology & Radiological Sciences, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, USA
| | - Amanda J Cox
- Center for Diabetes Research, Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Matthew A Allison
- Department of Family Medicine and Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA
| | - Michael H Criqui
- Department of Family Medicine and Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA
| | - Don Bowden
- Center for Diabetes Research, Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA.,Internal Medicine/Endocrinology, Wake Forest School of Medicine, Winston-Salem, NC, USA.,Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - M Arfan Ikram
- Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands
| | - Dan Mellström
- Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Magnus K Karlsson
- Department of Orthopaedics and Clinical Sciences, Malmö University Hospital, Lund University, Malmö, Sweden
| | - John Carr
- Department of Radiology & Radiological Sciences, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, USA
| | - Matthew Budoff
- Los Angeles Biomedical Research Institute, Torrance, CA, USA
| | - Caroline Phillips
- National Institute on Aging (NIA), National Institutes of Health, Bethesda, MD, USA
| | - L Adrienne Cupples
- Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
| | - Wen-Chi Chou
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | | | - Stuart H Ralston
- Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland, UK
| | - Kaare M Gautvik
- Lovisenberg Diakonale Hospital, Oslo, Norway.,Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
| | - Peggy M Cawthon
- California Pacific Medical Center Research Institute, San Francisco, CA, USA.,Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA
| | - Steven Cummings
- California Pacific Medical Center Research Institute, San Francisco, CA, USA
| | - David Karasik
- Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, MA, USA.,Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, Israel
| | - Fernando Rivadeneira
- Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands.,Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
| | - Vilmundur Gudnason
- Icelandic Heart Association, Kópavogur, Iceland.,Faculty of Medicine, University of Iceland, Reykjavík, Iceland
| | - Eric S Orwoll
- Division of Endocrinology, Oregon Health & Science University, Portland, OR, USA
| | - Tamara B Harris
- National Institute on Aging (NIA), National Institutes of Health, Bethesda, MD, USA
| | - Claes Ohlsson
- Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Douglas P Kiel
- Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, MA, USA.,Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University Medical School, Boston, MA, USA
| | - Yi-Hsiang Hsu
- Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, MA, USA.,Broad Institute of MIT and Harvard, Cambridge, MA, USA.,Molecular and Integrative Physiological Sciences, Harvard School of Public Health, Boston, MA, USA
| |
Collapse
|
12
|
Abstract
DNA methylation in eukaryotes invokes heritable alterations of the of the cytosine base in DNA without changing the underlying genomic DNA sequence. DNA methylation may be modified by environmental exposures as well as gene polymorphisms and may be a mechanistic link between environmental risk factors and the development of disease. In this review, we consider the role of DNA methylation in bone cells (osteoclasts/osteoblasts/osteocytes) and their progenitors with special focus on in vitro and ex vivo analyses. The number of studies on DNA methylation in bone cells is still somewhat limited, nevertheless it is getting increasingly clear that this type of the epigenetic changes is a critical regulator of gene expression. DNA methylation is necessary for proper development and function of bone cells and is accompanied by disease characteristic functional alterations as presently reviewed including postmenopausal osteoporosis and mechanical strain.
Collapse
Affiliation(s)
- Sjur Reppe
- Oslo University Hospital, Department of Medical Biochemistry, Oslo, Norway; ; Lovisenberg Diakonale Hospital, Oslo, Norway;; University of Oslo, Institute of Basic Medical Sciences, Oslo, Norway
| | - Harish Datta
- Newcastle University, Institute of Cellular Medicine, UK
| | - Kaare M Gautvik
- Lovisenberg Diakonale Hospital, Oslo, Norway;; University of Oslo, Institute of Basic Medical Sciences, Oslo, Norway
| |
Collapse
|
13
|
LeBlanc M, Zuber V, Andreassen BK, Witoelar A, Zeng L, Bettella F, Wang Y, McEvoy LK, Thompson WK, Schork AJ, Reppe S, Barrett-Connor E, Ligthart S, Dehghan A, Gautvik KM, Nelson CP, Schunkert H, Samani NJ, Ridker PM, Chasman DI, Aukrust P, Djurovic S, Frigessi A, Desikan RS, Dale AM, Andreassen OA. Identifying Novel Gene Variants in Coronary Artery Disease and Shared Genes With Several Cardiovascular Risk Factors. Circ Res 2015; 118:83-94. [PMID: 26487741 DOI: 10.1161/circresaha.115.306629] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2014] [Accepted: 10/20/2015] [Indexed: 01/02/2023]
Abstract
RATIONALE Coronary artery disease (CAD) is a critical determinant of morbidity and mortality. Previous studies have identified several cardiovascular disease risk factors, which may partly arise from a shared genetic basis with CAD, and thus be useful for discovery of CAD genes. OBJECTIVE We aimed to improve discovery of CAD genes and inform the pathogenic relationship between CAD and several cardiovascular disease risk factors using a shared polygenic signal-informed statistical framework. METHODS AND RESULTS Using genome-wide association studies summary statistics and shared polygenic pleiotropy-informed conditional and conjunctional false discovery rate methodology, we systematically investigated genetic overlap between CAD and 8 traits related to cardiovascular disease risk factors: low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, type 2 diabetes mellitus, C-reactive protein, body mass index, systolic blood pressure, and type 1 diabetes mellitus. We found significant enrichment of single-nucleotide polymorphisms associated with CAD as a function of their association with low-density lipoprotein, high-density lipoprotein, triglycerides, type 2 diabetes mellitus, C-reactive protein, body mass index, systolic blood pressure, and type 1 diabetes mellitus. Applying the conditional false discovery rate method to the enriched phenotypes, we identified 67 novel loci associated with CAD (overall conditional false discovery rate <0.01). Furthermore, we identified 53 loci with significant effects in both CAD and at least 1 of low-density lipoprotein, high-density lipoprotein, triglycerides, type 2 diabetes mellitus, C-reactive protein, systolic blood pressure, and type 1 diabetes mellitus. CONCLUSIONS The observed polygenic overlap between CAD and cardiometabolic risk factors indicates a pathogenic relation that warrants further investigation. The new gene loci identified implicate novel genetic mechanisms related to CAD.
Collapse
Affiliation(s)
- Marissa LeBlanc
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Verena Zuber
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Bettina Kulle Andreassen
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Aree Witoelar
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Lingyao Zeng
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Francesco Bettella
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Yunpeng Wang
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Linda K McEvoy
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Wesley K Thompson
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Andrew J Schork
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Sjur Reppe
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Elizabeth Barrett-Connor
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Symen Ligthart
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Abbas Dehghan
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Kaare M Gautvik
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Christopher P Nelson
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Heribert Schunkert
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Nilesh J Samani
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | | | - Paul M Ridker
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Daniel I Chasman
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Pål Aukrust
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Srdjan Djurovic
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Arnoldo Frigessi
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Rahul S Desikan
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Anders M Dale
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| | - Ole A Andreassen
- From the Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.L., B.K.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, and Research Support Services, Oslo University Hospital, Oslo, Norway (M.L., A.F.); NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (V.Z., A.W., F.B., Y.W., S.D., O.A.A.); Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (V.Z., A.W., F.B., S.D., O.A.A.); Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway (B.K.A.); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (L.Z., H.S.); Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Munich Heart Alliance, Munich, Germany (L.Z., H.S.); Multimodal Imaging Laboratory, University of California at San Diego, La Jolla (Y.W., L.K.M., A.J.S., R.S.D., A.M.D., O.A.A.); Department of Neurosciences, University of California, San Diego, La Jolla, (Y.W., A.M.D.); Department of Radiology, University of California, San Diego, La Jolla (L.K.M., R.S.D., A.M.D.); Department of Psychiatry, University of California, San Diego, La Jolla (W.K.T., A.M.D.); Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, (A.J.S.); Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway (S.R.); Department of Medical Biochemistry, Lovisenberg Diakonale Hospital, Oslo, Norway (S.R., K.M.G.); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (S.R., K.M.G.); Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, La Jolla (E.B.-C.); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (S.L., A.D.); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (C.P.N
| |
Collapse
|
14
|
Reppe S, Noer A, Grimholt RM, Halldórsson BV, Medina-Gomez C, Gautvik VT, Olstad OK, Berg JP, Datta H, Estrada K, Hofman A, Uitterlinden AG, Rivadeneira F, Lyle R, Collas P, Gautvik KM. Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women. J Bone Miner Res 2015; 30:249-56. [PMID: 25155887 DOI: 10.1002/jbmr.2342] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2014] [Revised: 07/27/2014] [Accepted: 08/12/2014] [Indexed: 12/31/2022]
Abstract
Inhibition of sclerostin, a glycoprotein secreted by osteocytes, offers a new therapeutic paradigm for treatment of osteoporosis (OP) through its critical role as Wnt/catenin signaling regulator. This study describes the epigenetic regulation of SOST expression in bone biopsies of postmenopausal women. We correlated serum sclerostin to bone mineral density (BMD), fractures, and bone remodeling parameters, and related these findings to epigenetic and genetic disease mechanisms. Serum sclerostin and bone remodeling biomarkers were measured in two postmenopausal groups: healthy (BMD T-score > -1) and established OP (BMD T-score < -2.5, with at least one low-energy fracture). Bone specimens were used to analyze SOST mRNAs, single nucleotide polymorphisms (SNPs), and DNA methylation changes. The SOST gene promoter region showed increased CpG methylation in OP patients (n = 4) compared to age and body mass index (BMI) balanced controls (n = 4) (80.5% versus 63.2%, p = 0.0001) with replication in independent cohorts (n = 27 and n = 36, respectively). Serum sclerostin and bone SOST mRNA expression correlated positively with age-adjusted and BMI-adjusted total hip BMD (r = 0.47 and r = 0.43, respectively; both p < 0.0005), and inversely to serum bone turnover markers. Five SNPs, one of which replicates in an independent population-based genomewide association study (GWAS), showed association with serum sclerostin or SOST mRNA levels under an additive model (p = 0.0016 to 0.0079). Genetic and epigenetic changes in SOST influence its bone mRNA expression and serum sclerostin levels in postmenopausal women. The observations suggest that increased SOST promoter methylation seen in OP is a compensatory counteracting mechanism, which lowers serum sclerostin concentrations and reduces inhibition of Wnt signaling in an attempt to promote bone formation.
Collapse
Affiliation(s)
- Sjur Reppe
- Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway; Lovisenberg Diakonale Hospital, Oslo, Norway; Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Benestad HB, Fossum S, Gautvik KM, Storm-Mathisen J, Storm-Mathisen I, Vaage JT. MINNEORD. Tidsskriftet 2015. [DOI: 10.4045/tidsskr.15.0846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open
|
16
|
Capulli M, Olstad OK, Onnerfjord P, Tillgren V, Muraca M, Gautvik KM, Heinegård D, Rucci N, Teti A. The C-terminal domain of chondroadherin: a new regulator of osteoclast motility counteracting bone loss. J Bone Miner Res 2014; 29:1833-46. [PMID: 24616121 DOI: 10.1002/jbmr.2206] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2013] [Revised: 01/23/2014] [Accepted: 02/06/2014] [Indexed: 11/12/2022]
Abstract
Chondroadherin (CHAD) is a leucine-rich protein promoting cell attachment through binding to integrin α2 β1 and syndecans. We observed that CHAD mRNA and protein were lower in bone biopsies of 50-year-old to 65-year-old osteoporotic women and in bone samples of ovariectomized mice versus gender/age-matched controls, suggesting a role in bone metabolism. By the means of an internal cyclic peptide (cyclicCHAD), we observed that its integrin binding sequence impaired preosteoclast migration through a nitric oxide synthase 2-dependent mechanism, decreasing osteoclastogenesis and bone resorption in a concentration-dependent fashion, whereas it had no effect on osteoblasts. Consistently, cyclicCHAD reduced transcription of two nitric oxide downstream genes, migfilin and vasp, involved in cell motility. Furthermore, the nitric oxide donor, S-nitroso-N-acetyl-D,L-penicillamine, stimulated preosteoclast migration and prevented the inhibitory effect of cyclicCHAD. Conversely, the nitric oxide synthase 2 (NOS2) inhibitor, N5-(1-iminoethyl)-l-ornithine, decreased both preosteoclast migration and differentiation, confirming a role of the nitric oxide pathway in the mechanism of action triggered by cyclicCHAD. In vivo, administration of cyclicCHAD was well tolerated and increased bone volume in healthy mice, with no adverse effect. In ovariectomized mice cyclicCHAD improved bone mass by both a preventive and a curative treatment protocol, with an effect in line with that of the bisphosphonate alendronate, that was mimicked by the NOS2 inhibitor [L-N6-(1-Iminoethyl)-lysine.2 dihydrochloride]. In both mouse models, cyclicCHAD reduced osteoclast and bone resorption without affecting osteoblast parameters and bone formation. In conclusion, CHAD is a novel regulator of bone metabolism that, through its integrin binding domain, inhibits preosteoclast motility and bone resorption, with a potential translational impact for the treatment of osteoporosis.
Collapse
Affiliation(s)
- Mattia Capulli
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Heier MS, Skinningsrud A, Paus E, Gautvik KM. Increased cerebrospinal fluid levels of nerve cell biomarkers in narcolepsy with cataplexy. Sleep Med 2014; 15:614-8. [PMID: 24784789 DOI: 10.1016/j.sleep.2014.02.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/01/2013] [Revised: 01/22/2014] [Accepted: 02/05/2014] [Indexed: 01/15/2023]
Abstract
BACKGROUND The association between narcolepsy with cataplexy and the hypocretinergic system in the central nervous system is strong since up to 75-90% of all patients have cerebrospinal fluid (CSF) hypocretin-1 deficiency. The predominant occurrence of HLADQB1*0602 tissue type in narcolepsy patients and recent results from genome-wide association studies suggest an underlying immunological mechanism. The present study was initiated to clarify whether measurement of nerve cell biomarkers in CSF could give additional knowledge of the pathophysiological mechanisms causing narcolepsy with cataplexy. METHODS Two patient groups with narcolepsy, comprising 18 patients with low CSF hypocretin-1 concentrations and typical cataplexy, and 18 patients with normal CSF hypocretin-1 levels and mild cataplexy-like symptoms, were compared to 17 controls. We measured the nerve cell biomarkers beta-amyloid (Aβ42), total tau protein (T-tau), phosphorylated tau (P-tau) and neuron-specific enolase (NSE) in CSF. RESULTS The concentrations of all biomarkers were significantly elevated in both patient groups compared to the controls. The concentration of beta-amyloid was significantly higher in the patient group with normal CSF hypocretin-1 concentration than in those with low concentrations, whereas the other biomarkers showed no difference between the patient groups. CONCLUSION The findings of elevated levels of CSF biomarkers independent of CSF hypocretin-1 reduction may reflect alterations in cell metabolism. The results suggest a more extensive affection of the sleep regulating cellular network, affecting other neuronal sites important in the regulation of sleep, in addition to the hypocretin-producing neurons.
Collapse
Affiliation(s)
- M S Heier
- Norwegian Resource Center for AD/HD, Tourette's Syndrome and Narcolepsy, Oslo University Hospital, Oslo, Norway.
| | - A Skinningsrud
- Department of Multidisciplinary Laboratory Medicine and Medical Biochemistry, Akershus University Hospital, Lørenskog, Norway
| | - E Paus
- Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway
| | - K M Gautvik
- Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway
| |
Collapse
|
18
|
Vilming Elgaaen B, Olstad OK, Haug KBF, Brusletto B, Sandvik L, Staff AC, Gautvik KM, Davidson B. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. BMC Cancer 2014; 14:80. [PMID: 24512620 PMCID: PMC3928323 DOI: 10.1186/1471-2407-14-80] [Citation(s) in RCA: 87] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2013] [Accepted: 02/07/2014] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Improved insight into the molecular characteristics of the different ovarian cancer subgroups is needed for developing a more individualized and optimized treatment regimen. The aim of this study was to a) identify differentially expressed miRNAs in high-grade serous ovarian carcinoma (HGSC), clear cell ovarian carcinoma (CCC) and ovarian surface epithelium (OSE), b) evaluate selected miRNAs for association with clinical parameters including survival and c) map miRNA-mRNA interactions. METHODS Differences in miRNA expression between HGSC, CCC and OSE were analyzed by global miRNA expression profiling (Affymetrix GeneChip miRNA 2.0 Arrays, n = 12, 9 and 9, respectively), validated by RT-qPCR (n = 35, 19 and 9, respectively), and evaluated for associations with clinical parameters. For HGSC, differentially expressed miRNAs were linked to differentially expressed mRNAs identified previously. RESULTS Differentially expressed miRNAs (n = 78) between HGSC, CCC and OSE were identified (FDR < 0.01%), of which 18 were validated (p < 0.01) using RT-qPCR in an extended cohort. Compared with OSE, miR-205-5p was the most overexpressed miRNA in HGSC. miR-200 family members and miR-182-5p were the most overexpressed in HGSC and CCC compared with OSE, whereas miR-383 was the most underexpressed. miR-205-5p and miR-200 members target epithelial-mesenchymal transition (EMT) regulators, apparently being important in tumor progression. miR-509-3-5p, miR-509-5p, miR-509-3p and miR-510 were among the strongest differentiators between HGSC and CCC, all being significantly overexpressed in CCC compared with HGSC. High miR-200c-3p expression was associated with poor progression-free (p = 0.031) and overall (p = 0.026) survival in HGSC patients. Interacting miRNA and mRNA targets, including those of a TP53-related pathway presented previously, were identified in HGSC. CONCLUSIONS Several miRNAs differentially expressed between HGSC, CCC and OSE have been identified, suggesting a carcinogenetic role for these miRNAs. miR-200 family members, targeting EMT drivers, were mostly overexpressed in both subgroups, among which miR-200c-3p was associated with survival in HGSC patients. A set of miRNAs differentiates CCC from HGSC, of which miR-509-3-5p and miR-509-5p are the strongest classifiers. Several interactions between miRNAs and mRNAs in HGSC were mapped.
Collapse
Affiliation(s)
- Bente Vilming Elgaaen
- Department of Gynecological Oncology, Oslo University Hospital (OUH), The Norwegian Radium Hospital, Postbox 4953 Nydalen 0424, Oslo, Norway.
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Jensen K, Rother MB, Brusletto BS, Olstad OK, Dalsbotten Aass HC, van Zelm MC, Kierulf P, Gautvik KM. Increased ID2 levels in adult precursor B cells as compared with children is associated with impaired Ig locus contraction and decreased bone marrow output. J Immunol 2013; 191:1210-9. [PMID: 23825313 DOI: 10.4049/jimmunol.1203462] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Precursor B cell production from bone marrow in mice and humans declines with age. Because the mechanisms behind are still unknown, we studied five precursor B cell subsets (ProB, PreBI, PreBII large, PreBII small, immature B) and their differentiation-stage characteristic gene expression profiles in healthy individual toddlers and middle-aged adults. Notably, the composition of the precursor B cell compartment did not change with age. The expression levels of several transcripts encoding V(D)J recombination factors were decreased in adults as compared with children: RAG1 expression was significantly reduced in ProB cells, and DNA-PKcs, Ku80, and XRCC4 were decreased in PreBI cells. In contrast, TdT was 3-fold upregulated in immature B cells of adults. Still, N-nucleotides, P-nucleotides, and deletions were similar for IGH and IGK junctions between children and adults. PreBII large cells in adults, but not in children, showed highly upregulated expression of the differentiation inhibitor, inhibitor of DNA binding 2 (ID2), in absence of changes in expression of the ID2-binding partner E2A. Further, we identified impaired Ig locus contraction in adult precursor B cells as a likely mechanism by which ID2-mediated blocking of E2A function results in reduced bone marrow B cell output in adults. The reduced B cell production was not compensated by increased proliferation in adult immature B cells, despite increased Ki67 expression. These findings demonstrate distinct regulatory mechanisms in B cell differentiation between adults and children with a central role for transcriptional regulation of ID2.
Collapse
Affiliation(s)
- Kristin Jensen
- Department of Medical Biochemistry, Oslo University Hospital, 0407 Oslo, Norway.
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Reppe S, Sachse D, Olstad OK, Gautvik VT, Sanderson P, Datta HK, Berg JP, Gautvik KM. Identification of transcriptional macromolecular associations in human bone using browser based in silico analysis in a giant correlation matrix. Bone 2013. [PMID: 23195995 DOI: 10.1016/j.bone.2012.11.015] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Intracellular signaling is critically dependent on gene regulatory networks comprising physical molecular interactions. Presently, there is a lack of comprehensive databases for most human tissue types to verify such macromolecular interactions. We present a user friendly browser which helps to identify functional macromolecular interactions in human bone as significant correlations at the transcriptional level. The molecular skeletal phenotype has been characterized by transcriptome analysis of iliac crest bone biopsies from 84 postmenopausal women through quantifications of ~23,000 mRNA species. When the signal levels were inter-correlated, an array containing >260 million correlations was generated, thus recognizing the human bone interactome at the RNA level. The matrix correlation and p values were made easily accessible by a freely available online browser. We show that significant correlations within the giant matrix are reproduced in a replica set of 13 male vertebral biopsies. The identified correlations differ somewhat from transcriptional interactions identified in cell culture experiments and transgenic mice, thus demonstrating that care should be taken in extrapolating such results to the in vivo situation in human bone. The current giant matrix and web browser are a valuable tool for easy access to the human bone transcriptome and molecular interactions represented as significant correlations at the RNA-level. The browser and matrix should be a valuable hypothesis generating tool for identification of regulatory mechanisms and serve as a library of transcript relationships in human bone, a relatively inaccessible tissue.
Collapse
Affiliation(s)
- Sjur Reppe
- Department of Medical Biochemistry, Oslo University Hospital, Ullevaal, Norway.
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Elgaaen BV, Olstad OK, Sandvik L, Odegaard E, Sauer T, Staff AC, Gautvik KM. ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival. PLoS One 2012; 7:e46317. [PMID: 23029477 PMCID: PMC3460818 DOI: 10.1371/journal.pone.0046317] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2012] [Accepted: 08/29/2012] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND The oncogenesis of ovarian cancer is poorly understood. The aim of this study was to identify mRNAs differentially expressed between moderately and poorly differentiated (MD/PD) serous ovarian carcinomas (SC), serous ovarian borderline tumours (SBOT) and superficial scrapings from normal ovaries (SNO), and to correlate these mRNAs with clinical parameters including survival. METHODS Differences in mRNA expression between MD/PD SC, SBOT and SNO were analyzed by global gene expression profiling (n = 23), validated by RT-qPCR (n = 41) and correlated with clinical parameters. RESULTS Thirty mRNAs differentially expressed between MD/PD SC, SBOT and SNO were selected from the global gene expression analyses, and 21 were verified (p<0.01) by RT-qPCR. Of these, 13 mRNAs were differentially expressed in MD/PD SC compared with SNO (p<0.01) and were correlated with clinical parameters. ZNF385B was downregulated (FC = -130.5, p = 1.2×10(-7)) and correlated with overall survival (p = 0.03). VEGFA was upregulated (FC = 6.1, p = 6.0×10(-6)) and correlated with progression-free survival (p = 0.037). Increased levels of TPX2 and FOXM1 mRNAs (FC = 28.5, p = 2.7×10(-10) and FC = 46.2, p = 5.6×10(-4), respectively) correlated with normalization of CA125 (p = 0.03 and p = 0.044, respectively). Furthermore, we present a molecular pathway for MD/PD SC, including VEGFA, FOXM1, TPX2, BIRC5 and TOP2A, all significantly upregulated and directly interacting with TP53. CONCLUSIONS We have identified 21 mRNAs differentially expressed (p<0.01) between MD/PD SC, SBOT and SNO. Thirteen were differentially expressed in MD/PD SC, including ZNF385B and VEGFA correlating with survival, and FOXM1 and TPX2 with normalization of CA125. We also present a molecular pathway for MD/PD SC.
Collapse
|
22
|
Medina-Gomez C, Kemp JP, Estrada K, Eriksson J, Liu J, Reppe S, Evans DM, Heppe DHM, Vandenput L, Herrera L, Ring SM, Kruithof CJ, Timpson NJ, Zillikens MC, Olstad OK, Zheng HF, Richards JB, St. Pourcain B, Hofman A, Jaddoe VWV, Smith GD, Lorentzon M, Gautvik KM, Uitterlinden AG, Brommage R, Ohlsson C, Tobias JH, Rivadeneira F. Meta-analysis of genome-wide scans for total body BMD in children and adults reveals allelic heterogeneity and age-specific effects at the WNT16 locus. PLoS Genet 2012; 8:e1002718. [PMID: 22792070 PMCID: PMC3390371 DOI: 10.1371/journal.pgen.1002718] [Citation(s) in RCA: 129] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2011] [Accepted: 04/04/2012] [Indexed: 12/31/2022] Open
Abstract
To identify genetic loci influencing bone accrual, we performed a genome-wide association scan for total-body bone mineral density (TB-BMD) variation in 2,660 children of different ethnicities. We discovered variants in 7q31.31 associated with BMD measurements, with the lowest P = 4.1×10−11 observed for rs917727 with minor allele frequency of 0.37. We sought replication for all SNPs located ±500 kb from rs917727 in 11,052 additional individuals from five independent studies including children and adults, together with de novo genotyping of rs3801387 (in perfect linkage disequilibrium (LD) with rs917727) in 1,014 mothers of children from the discovery cohort. The top signal mapping in the surroundings of WNT16 was replicated across studies with a meta-analysis P = 2.6×10−31 and an effect size explaining between 0.6%–1.8% of TB-BMD variance. Conditional analyses on this signal revealed a secondary signal for total body BMD (P = 1.42×10−10) for rs4609139 and mapping to C7orf58. We also examined the genomic region for association with skull BMD to test if the associations were independent of skeletal loading. We identified two signals influencing skull BMD variation, including rs917727 (P = 1.9×10−16) and rs7801723 (P = 8.9×10−28), also mapping to C7orf58 (r2 = 0.50 with rs4609139). Wnt16 knockout (KO) mice with reduced total body BMD and gene expression profiles in human bone biopsies support a role of C7orf58 and WNT16 on the BMD phenotypes observed at the human population level. In summary, we detected two independent signals influencing total body and skull BMD variation in children and adults, thus demonstrating the presence of allelic heterogeneity at the WNT16 locus. One of the skull BMD signals mapping to C7orf58 is mostly driven by children, suggesting temporal determination on peak bone mass acquisition. Our life-course approach postulates that these genetic effects influencing peak bone mass accrual may impact the risk of osteoporosis later in life. Genetic investigations on bone mineral density (BMD) variation in children allow the identification of factors determining peak bone mass and their influence on developing osteoporosis later in life. We ran a genome-wide association study (GWAS) for total body BMD based on 2,660 children of different ethnic backgrounds, followed by replication in an additional 12,066 individuals comprising children, young adults, and elderly populations. Our GWAS meta-analysis identified two independent signals in the 7q31.31 locus, arising from SNPs in the vicinity of WNT16, FAM3C, and C7orf58. These variants were also associated with skull BMD, a skeletal trait with much less environmental influence for which one of the signals displayed age-specific effects. Integration of functional studies in a Wnt16 knockout mouse model and gene expression profiles in human bone tissue provided additional evidence that WNT16 and C7orf58 underlie the described associations. All together our findings demonstrate the relevance of these factors for bone biology, the attainment of peak bone mass, and their likely impact on bone fragility later in life.
Collapse
Affiliation(s)
- Carolina Medina-Gomez
- Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
- The Generation R Study Group, Erasmus University Medical Center, Rotterdam, The Netherlands
- Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands
- Netherlands Genomics Initiative (NGI)–sponsored Netherlands Consortium for Healthy Aging (NCHA), Rotterdam, The Netherlands
| | - John P. Kemp
- MRC CAiTE Centre, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
- Avon Longitudinal Study of Parents and Children (ALSPAC), School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
| | - Karol Estrada
- Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
- Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands
- Netherlands Genomics Initiative (NGI)–sponsored Netherlands Consortium for Healthy Aging (NCHA), Rotterdam, The Netherlands
| | - Joel Eriksson
- Center for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Jeff Liu
- Lexicon Pharmaceuticals, The Woodlands, Texas, United States of America
| | - Sjur Reppe
- Department of Medical Biochemistry, Oslo University Hospital, Ullevaal, Oslo, Norway
| | - David M. Evans
- MRC CAiTE Centre, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
- Avon Longitudinal Study of Parents and Children (ALSPAC), School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
| | - Denise H. M. Heppe
- The Generation R Study Group, Erasmus University Medical Center, Rotterdam, The Netherlands
- Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands
- Department of Pediatrics, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Liesbeth Vandenput
- Center for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Lizbeth Herrera
- Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Susan M. Ring
- Avon Longitudinal Study of Parents and Children (ALSPAC), School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
| | - Claudia J. Kruithof
- The Generation R Study Group, Erasmus University Medical Center, Rotterdam, The Netherlands
- Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Nicholas J. Timpson
- MRC CAiTE Centre, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
- Avon Longitudinal Study of Parents and Children (ALSPAC), School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
| | - M. Carola Zillikens
- Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
- Netherlands Genomics Initiative (NGI)–sponsored Netherlands Consortium for Healthy Aging (NCHA), Rotterdam, The Netherlands
| | - Ole K. Olstad
- Department of Medical Biochemistry, Oslo University Hospital, Ullevaal, Oslo, Norway
| | - Hou-Feng Zheng
- Department of Medicine, Human Genetics, McGill University, Montreal, Quebec, Canada
- Department of Epidemiology and Biostatistics, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
| | - J. Brent Richards
- Department of Medicine, Human Genetics, McGill University, Montreal, Quebec, Canada
- Department of Epidemiology and Biostatistics, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
- Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom
| | - Beate St. Pourcain
- MRC CAiTE Centre, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
| | - Albert Hofman
- The Generation R Study Group, Erasmus University Medical Center, Rotterdam, The Netherlands
- Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands
- Netherlands Genomics Initiative (NGI)–sponsored Netherlands Consortium for Healthy Aging (NCHA), Rotterdam, The Netherlands
| | - Vincent W. V. Jaddoe
- The Generation R Study Group, Erasmus University Medical Center, Rotterdam, The Netherlands
- Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands
- Department of Pediatrics, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - George Davey Smith
- MRC CAiTE Centre, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
- Avon Longitudinal Study of Parents and Children (ALSPAC), School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
| | - Mattias Lorentzon
- Center for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Kaare M. Gautvik
- Department of Medical Biochemistry, Oslo University Hospital, Ullevaal, Oslo, Norway
- Department of Medical Biochemistry, Oslo Deacon Hospital, Oslo, Norway
| | - André G. Uitterlinden
- Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
- The Generation R Study Group, Erasmus University Medical Center, Rotterdam, The Netherlands
- Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands
- Netherlands Genomics Initiative (NGI)–sponsored Netherlands Consortium for Healthy Aging (NCHA), Rotterdam, The Netherlands
| | - Robert Brommage
- Lexicon Pharmaceuticals, The Woodlands, Texas, United States of America
| | - Claes Ohlsson
- Center for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Jonathan H. Tobias
- School of Clinical Sciences, University of Bristol, Bristol, United Kingdom
| | - Fernando Rivadeneira
- Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
- The Generation R Study Group, Erasmus University Medical Center, Rotterdam, The Netherlands
- Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands
- Netherlands Genomics Initiative (NGI)–sponsored Netherlands Consortium for Healthy Aging (NCHA), Rotterdam, The Netherlands
- * E-mail:
| |
Collapse
|
23
|
Heier MS, Jansson TS, Gautvik KM. Cerebrospinal fluid hypocretin 1 deficiency, overweight, and metabolic dysregulation in patients with narcolepsy. J Clin Sleep Med 2012; 7:653-8. [PMID: 22171205 DOI: 10.5664/jcsm.1474] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
STUDY OBJECTIVES The possible relationship between cerebrospinal fluid (CSF) hypocretin and leptin levels, overweight, and association to risk factors for diabetes 2 in narcolepsy with cataplexy were compared to patients with idiopathic hypersomnia and controls. PATIENTS 26 patients with narcolepsy, cataplexy, and hypocretin deficiency; 23 patients with narcolepsy, cataplexy, and normal hypocretin values; 11 patients with idiopathic hypersomnia; and 43 controls. MEASUREMENTS AND RESULTS Body mass index (BMI), serum leptin, and HbA1C were measured in patients and controls; and CSF hypocretin 1 and leptin measured in all patients. Female and male patients with narcolepsy and hypocretin deficiency had the highest mean BMI (27.8 and 26.2, respectively), not statistically different from patients with narcolepsy and normal hypocretin or controls, but statistically higher than the patients with idiopathic hypersomnia (p < 0.001 and 0.011, respectively). The number of obese patients (BMI > 30) was increased in both narcolepsy groups. Serum and CSF leptin levels correlated positively to BMI in patients and controls, but not to CSF hypocretin concentrations. HbA1C was within normal levels and similar in all groups. CONCLUSIONS The study confirms a moderate tendency to obesity (BMI > 30) and overweight in patients with narcolepsy and cataplexy. Obesity was not correlated to hypocretin deficiency or reduced serum or CSF leptin concentrations. We suggest that overweight and possible metabolic changes previously reported in narcolepsy, may be caused by other mechanisms.
Collapse
Affiliation(s)
- Mona S Heier
- Department of Clinical Neurophysiology, Oslo University Hospital, Ullevål, Oslo, Norway.
| | | | | |
Collapse
|
24
|
Jemtland R, Holden M, Reppe S, Olstad OK, Reinholt FP, Gautvik VT, Refvem H, Frigessi A, Houston B, Gautvik KM. Molecular disease map of bone characterizing the postmenopausal osteoporosis phenotype. J Bone Miner Res 2011; 26:1793-801. [PMID: 21452281 DOI: 10.1002/jbmr.396] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Genome-wide gene expressions in bone biopsies from patients with postmenopausal osteoporosis and healthy controls were profiled, to identify osteoporosis candidate genes. All osteoporotic patients (n = 27) in an unbiased cohort of Norwegian women presented with bone mineral density (BMD) T-scores of less than -2.5 SD and one or more confirmed low-energy fracture(s). A validation group (n = 18) had clinical and laboratory parameters intermediate to the control (n = 39) and osteoporosis groups. RNA from iliac crest bone biopsies were analyzed by Affymetrix microarrays and real-time reverse-transcriptase polymerase chain reaction (RT-PCR). Differentially expressed genes in osteoporosis versus control groups were identified using the Bayesian ANOVA for microarrays (BAMarray) method, whereas the R-package Limma (Linear Models for Microarray Data) was used to determine whether these transcripts were explained by disease, age, body mass index (BMI), or combinations thereof. Laboratory tests showed normal ranges for the cohort. A total of 609 transcripts were differentially expressed in osteoporotic patients relative to controls; 256 transcripts were confirmed for disease when controlling for age or BMI. Most of the osteoporosis susceptibility genes (80%) also were confirmed to be regulated in the same direction in the validation group. Furthermore, 217 of 256 transcripts were correlated with BMD (adjusted for age and BMI) at various skeletal sites (|r| > 0.2, p < .05). Among the most distinctly expressed genes were Wnt antagonists DKK1 and SOST, the transcription factor SOX4, and the bone matrix proteins MMP13 and MEPE, all reduced in osteoporosis versus control groups. Our results identify potential osteoporosis susceptibility candidate genes adjusted for confounding factors (ie, age and BMI) with or without a significant correlation with BMD.
Collapse
Affiliation(s)
- Rune Jemtland
- Section of Endocrinology, Department of Medicine, Rikshospitalet University Hospital, Oslo, Norway
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Elgaaen BV, Haug KBF, Wang J, Olstad OK, Fortunati D, Onsrud M, Staff AC, Sauer T, Gautvik KM. POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas. PLoS One 2010; 5:e13837. [PMID: 21079801 PMCID: PMC2973954 DOI: 10.1371/journal.pone.0013837] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2010] [Accepted: 10/01/2010] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Epithelial ovarian cancer (EOC) constitutes more than 90% of ovarian cancers and is associated with high mortality. EOC comprises a heterogeneous group of tumours, and the causes and molecular pathology are essentially unknown. Improved insight into the molecular characteristics of the different subgroups of EOC is urgently needed, and should eventually lead to earlier diagnosis as well as more individualized and effective treatments. Previously, we reported a limited number of mRNAs strongly upregulated in human osteosarcomas and other malignancies, and six were selected to be tested for a possible association with three subgroups of ovarian carcinomas and clinical parameters. METHODOLOGY/PRINCIPAL FINDINGS The six selected mRNAs were quantified by RT-qPCR in biopsies from eleven poorly differentiated serous carcinomas (PDSC, stage III-IV), twelve moderately differentiated serous carcinomas (MDSC, stage III-IV) and eight clear cell carcinomas (CCC, stage I-IV) of the ovary. Superficial scrapings from six normal ovaries (SNO), as well as biopsies from three normal ovaries (BNO) and three benign ovarian cysts (BBOC) were analyzed for comparison. The gene expression level was related to the histological and clinical parameters of human ovarian carcinoma samples. One of the mRNAs, DNA polymerase delta 2 small subunit (POLD2), was increased in average 2.5- to almost 20-fold in MDSC and PDSC, respectively, paralleling the degree of dedifferentiation and concordant with a poor prognosis. Except for POLD2, the serous carcinomas showed a similar transcription profile, being clearly different from CCC. Another mRNA, Killer-specific secretory protein of 37 kDa (KSP37) showed six- to eight-fold higher levels in CCC stage I compared with the more advanced staged carcinomas, and correlated positively with an improved clinical outcome. CONCLUSIONS/SIGNIFICANCE We have identified two biomarkers which are markedly upregulated in two subgroups of ovarian carcinomas and are also associated with stage and outcome. The results suggest that POLD2 and KSP37 might be potential prognostic biomarkers.
Collapse
|
26
|
Fortunati D, Reppe S, Fjeldheim AK, Nielsen M, Gautvik VT, Gautvik KM. Periostin is a collagen associated bone matrix protein regulated by parathyroid hormone. Matrix Biol 2010; 29:594-601. [PMID: 20654714 DOI: 10.1016/j.matbio.2010.07.001] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2009] [Revised: 05/27/2010] [Accepted: 07/09/2010] [Indexed: 11/18/2022]
Abstract
Periostin is a 90 kDa secreted protein, originally identified in murine osteoblast-like cells, with a distribution restricted to collagen-rich tissues and certain tumors. In this paper, we first analyzed the expression of periostin mRNA and protein in human fetal osteoblasts (hFOB) and human osteosarcoma (hOS) cell lines by RT real-time PCR and Western blot, respectively. The hFOB 1.19 and three hOS (MHM, KPDXM and Eggen) showed highly variable periostin mRNA levels and protein. Second, we showed that the expression of periostin mRNA was inversely related to the cells' abilities to differentiate and mineralize. Then, we investigated the regulation of periostin mRNA in hFOB after siRNA treatment and in mouse primary osteoblasts (mOB) treated with PTH. Knock-down of periostin mRNA, down-regulated PTHrP, but did not affect the expression of other important markers of differentiation such as RUNX2. In addition, periostin mRNA was transiently up-regulated in osteoblasts by PTH. Finally, the localization of periostin and its partially co-localization with collagen 1a1 mRNA and protein was studied in mouse embryos and postnatal pups using in situ hybridization and immunohistochemistry, respectively. In conclusion, the present study provides novel observations related to the expression, distribution and regulation of periostin in bone cells and extracellular matrix.
Collapse
Affiliation(s)
- Dario Fortunati
- Department of Biochemistry, Institute of Basic Medical Sciences, PO Box 1112 Blindern, University of Oslo, N-0317 Oslo, Norway
| | | | | | | | | | | |
Collapse
|
27
|
Varanasi SS, Olstad OK, Swan DC, Sanderson P, Gautvik VT, Reppe S, Francis RM, Gautvik KM, Datta HK. Skeletal site-related variation in human trabecular bone transcriptome and signaling. PLoS One 2010; 5:e10692. [PMID: 20502692 PMCID: PMC2872667 DOI: 10.1371/journal.pone.0010692] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2009] [Accepted: 04/19/2010] [Indexed: 11/19/2022] Open
Abstract
Background The skeletal site-specific influence of multiple genes on bone morphology is recognised, but the question as to how these influences may be exerted at the molecular and cellular level has not been explored. Methodology To address this question, we have compared global gene expression profiles of human trabecular bone from two different skeletal sites that experience vastly different degrees of mechanical loading, namely biopsies from iliac crest and lumbar spinal lamina. Principal Findings In the lumbar spine, compared to the iliac crest, the majority of the differentially expressed genes showed significantly increased levels of expression; 3406 transcripts were up- whilst 838 were down-regulated. Interestingly, all gene transcripts that have been recently demonstrated to be markers of osteocyte, as well as osteoblast and osteoclast-related genes, were markedly up-regulated in the spine. The transcriptome data is consistent with osteocyte numbers being almost identical at the two anatomical sites, but suggesting a relatively low osteocyte functional activity in the iliac crest. Similarly, osteoblast and osteoclast expression data suggested similar numbers of the cells, but presented with higher activity in the spine than iliac crest. This analysis has also led to the identification of expression of a number of transcripts, previously known and novel, which to our knowledge have never earlier been associated with bone growth and remodelling. Conclusions and Significance This study provides molecular evidence explaining anatomical and micro-architectural site-related changes in bone cell function, which is predominantly attributable to alteration in cell transcriptional activity. A number of novel signaling molecules in critical pathways, which have been hitherto not known to be expressed in bone cells of mature vertebrates, were identified.
Collapse
Affiliation(s)
- Satya S Varanasi
- Musculoskeletal Research Group, Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle Upon Tyne, United Kingdom
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Kalogeropoulos M, Varanasi SS, Olstad OK, Sanderson P, Gautvik VT, Reppe S, Francis RM, Gautvik KM, Birch MA, Datta HK. Zic1 transcription factor in bone: neural developmental protein regulates mechanotransduction in osteocytes. FASEB J 2010; 24:2893-903. [DOI: 10.1096/fj.09-148908] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Michail Kalogeropoulos
- Musculoskeletal Research GroupInstitute of Cellular MedicineThe Medical School Newcastle upon Tyne UK
| | - Satya S. Varanasi
- Musculoskeletal Research GroupInstitute of Cellular MedicineThe Medical School Newcastle upon Tyne UK
| | - Ole K. Olstad
- Department of Clinical ChemistryOslo University Hospital Ullevaal Oslo Norway
| | - Paul Sanderson
- Department of Orthopaedic SurgeryThe Newcastle upon Tyne NHS Foundation Trust Hospitals Newcastle upon Tyne UK
| | - Vigdis T. Gautvik
- Department of Clinical ChemistryLovisenberg Deacon Hospital Oslo Norway
| | - Sjur Reppe
- Department of Clinical ChemistryLovisenberg Deacon Hospital Oslo Norway
| | - Roger M. Francis
- Institute for Ageing and HealthNewcastle University Newcastle upon Tyne UK
| | - Kaare M. Gautvik
- Department of Clinical ChemistryOslo University Hospital Ullevaal Oslo Norway
- Department of Clinical ChemistryLovisenberg Deacon Hospital Oslo Norway
- Institute of Basic Medical SciencesUniversity of Oslo Oslo Norway
| | - Mark A. Birch
- Musculoskeletal Research GroupInstitute of Cellular MedicineThe Medical School Newcastle upon Tyne UK
| | - Harish K. Datta
- Musculoskeletal Research GroupInstitute of Cellular MedicineThe Medical School Newcastle upon Tyne UK
| |
Collapse
|
29
|
Gordeladze JO, Mortensen B, Nordal K, Halse J, Dahl E, Aksnes L, Gautvik KM. The effect of parathyroid hormone (PTH) and 24,25-dihydroxy-vitamin D3on adenylyl cyclase of iliac crest biopsies: Diagnostic and prognostic tool for evaluation and treatment of uremic patients. Scandinavian Journal of Clinical and Laboratory Investigation 2010. [DOI: 10.1080/00365518709168150] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
30
|
Reppe S, Refvem H, Gautvik VT, Olstad OK, Høvring PI, Reinholt FP, Holden M, Frigessi A, Jemtland R, Gautvik KM. Eight genes are highly associated with BMD variation in postmenopausal Caucasian women. Bone 2010; 46:604-12. [PMID: 19922823 DOI: 10.1016/j.bone.2009.11.007] [Citation(s) in RCA: 73] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2009] [Revised: 10/22/2009] [Accepted: 11/09/2009] [Indexed: 02/09/2023]
Abstract
Low bone mineral density (BMD) is an important risk factor for skeletal fractures which occur in about 40% of women >/=50 years in the western world. We describe the transcriptional changes in 84 trans-iliacal bone biopsies associated with BMD variations in postmenopausal females (50 to 86 years), aiming to identify genetic determinants of bone structure. The women were healthy or having a primary osteopenic or osteoporotic status with or without low energy fractures. The total cohort of 91 unrelated women representing a wide range of BMDs, were consecutively registered and submitted to global gene Affymetrix microarray expression analysis or histomorphometry. Among almost 23,000 expressed transcripts, a set represented by ACSL3 (acyl-CoA synthetase long-chain family member 3), NIPSNAP3B (nipsnap homolog 3B), DLEU2 (Deleted in lymphocytic leukemia, 2), C1ORF61 (Chromosome 1 open reading frame 61), DKK1 (Dickkopf homolog 1), SOST (Sclerostin), ABCA8, (ATP-binding cassette, sub-family A, member 8), and uncharacterized (AFFX-M27830-M-at), was significantly correlated to total hip BMD (5% false discovery rate) explaining 62% of the BMD variation expressed as T-score, 53% when adjusting for the influence of age (Z-score) and 44% when further adjusting for body mass index (BMI). Only SOST was previously associated to BMD, and the majority of the genes have previously not been associated with a bone phenotype. In molecular network analyses, SOST shows a strong, positive correlation with DKK1, both being members of the Wnt signaling pathway. The results provide novel insight in the underlying biology of bone metabolism and osteoporosis which is the ultimate consequence of low BMD.
Collapse
Affiliation(s)
- Sjur Reppe
- Institute of Basic Medical Sciences, University of Oslo, Norway.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Jensen K, Schaffer L, Olstad OK, Bechensteen AG, Hellebostad M, Tjønnfjord GE, Kierulf P, Gautvik KM, Osnes LTN. Striking decrease in the total precursor B-cell compartment during early childhood as evidenced by flow cytometry and gene expression changes. Pediatr Hematol Oncol 2010; 27:31-45. [PMID: 20121553 DOI: 10.3109/08880010903420687] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The number of circulating B-cells in peripheral blood plateaus between 2 and 24 months of age, and thereafter declines gradually. How this reflects the kinetics of the precursor B-cell pool in the bone marrow is of clinical interest, but has not been studied thoroughly in humans. The authors analyzed bone marrow (n = 37) from healthy children and adults (flow cytometry) searching for age-related changes in the total precursor B-cell compartment. In an age-matched cohort (n = 25) they examined age-related global gene expression changes (Affymetrix) in unsorted bone marrow with special reference to the recombination activating gene 1, RAG1. Subsequently, they searched the entire gene set for transcripts correlating to the RAG1 profile to discover other known and possibly new precursor B-cell related transcripts. Both methods disclosed a marked, transient increase of total precursor B-cells at 6-20 months, followed by a rapid decrease confined to the first 2 years. The decline thereafter was considerably slower, but continued until adulthood. The relative composition of total precursor B-cells, however, did not change significantly with age. The authors identified 54 genes that were highly correlated to the RAG1 profile (r >or= .9, p < 1 x 10(-8)). Of these 54 genes, 15 were characteristically B-lineage associated like CD19, CD79, VPREB, EBF1, and PAX5; the remaining 39 previously not described as distinctively B-lineage related. The marked, transient increase in precursor B-cells and RAG1 transcriptional activity is not reflected by a similar peak in B-cells in peripheral blood, whereas the sustained plateau concurs in time.
Collapse
Affiliation(s)
- Kristin Jensen
- Department of Pediatrics, Faculty Division Ullevål, University of Oslo, Oslo, Norway.
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Pedersen ME, Fortunati D, Nielsen M, Brorson SH, Lekva T, Nissen-Meyer LSH, Gautvik VT, Shahdadfar A, Gautvik KM, Jemtland R. Calmodulin-dependent kinase 1beta is expressed in the epiphyseal growth plate and regulates proliferation of mouse calvarial osteoblasts in vitro. Bone 2008; 43:700-7. [PMID: 18620088 DOI: 10.1016/j.bone.2008.06.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/13/2007] [Revised: 04/08/2008] [Accepted: 06/02/2008] [Indexed: 11/20/2022]
Abstract
The Ca(2+)/Calmodulin-dependent protein kinase (CaMK) family is activated in response to elevation of intracellular Ca(2+), and includes CaMK1 (as well as CaMK2 and CaMK4), which exists as different isoforms (alpha, beta, gamma and delta). CaMK1 is present in several cell types and may be involved in various cellular processes, but its role in bone is unknown. In situ hybridization was used to determine the spatial and temporal expression of CaMK1beta during endochondral bone development in mouse embryos and newborn pups. The cellular and subcellular distribution of CaMK1 was assessed by quantitative immunogold electron microscopy (EM). The role of CaMK1beta in mouse calvarial osteoblasts was investigated by using small interfering RNA (siRNA) to silence its expression, while in parallel monitoring cell proliferation and levels of skeletogenic transcripts. cRNA in situ hybridization and EM studies show that CaMK1beta is mainly located in developing long bones and vertebrae (from ED14.5 until day 10 after birth), with highest expression in epiphyseal growth plate hypertrophic chondrocytes. By RT-PCR, we show that CaMK1beta2 (but not beta1) is expressed in mouse hind limbs (in vivo) and mouse calvarial osteoblasts (in vitro), and also in primary human articular chondrocyte cultures. Silencing of CaMK1beta in mouse calvarial osteoblasts by siRNA significantly decreases osteoblast proliferation and c-Fos gene expression (approx. 50%), without affecting skeletogenic markers for more differentiated osteoblasts (i.e. Cbfa1/Runx2, Osterix (Osx), Osteocalcin (Oc), Alkaline phosphatase (Alp) and Osteopontin (Opn)). These results identify CaMK1beta as a novel regulator of osteoblast proliferation, via mechanisms that may at least in part involve c-Fos, thus implicating CaMK1beta in the regulation of bone and cartilage development.
Collapse
Affiliation(s)
- Mona E Pedersen
- Institute of Basic Medical Sciences, Department of Biochemistry, University of Oslo, Oslo, Norway
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Nissen-Meyer LSH, Jemtland R, Gautvik VT, Pedersen ME, Paro R, Fortunati D, Pierroz DD, Stadelmann VA, Reppe S, Reinholt FP, Del Fattore A, Rucci N, Teti A, Ferrari S, Gautvik KM. Osteopenia, decreased bone formation and impaired osteoblast development in Sox4 heterozygous mice. J Cell Sci 2007; 120:2785-95. [PMID: 17652162 DOI: 10.1242/jcs.003855] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
The transcription factor Sox4 is vital for fetal development, as Sox4–/– homozygotes die in utero. Sox4 mRNA is expressed in the early embryonic growth plate and is regulated by parathyroid hormone, but its function in bone modeling/remodeling is unknown. We report that Sox4+/– mice exhibit significantly lower bone mass (by dual-energy X-ray absorptiometry) from an early age, and fail to obtain the peak bone mass of wild-type (WT) animals. Microcomputed tomography (μCT), histomorphometry and biomechanical testing of Sox4+/– bones show reduced trabecular and cortical thickness, growth plate width, ultimate force and stiffness compared with WT. Bone formation rate (BFR) in 3-month-old Sox4+/– mice is 64% lower than in WT. Primary calvarial osteoblasts from Sox4+/– mice demonstrate markedly inhibited proliferation, differentiation and mineralization. In these cultures, osterix (Osx) and osteocalcin (OCN) mRNA expression was reduced, whereas Runx2 mRNA was unaffected. No functional defects were found in osteoclasts. Silencing of Sox4 by siRNA in WT osteoblasts replicated the defects observed in Sox4+/– cells. We demonstrate inhibited formation and altered microarchitecture of bone in Sox4+/– mice versus WT, without apparent defects in bone resorption. Our results implicate the transcription factor Sox4 in regulation of bone formation, by acting upstream of Osx and independent of Runx2.
Collapse
|
34
|
Reppe S, Stilgren L, Abrahamsen B, Olstad OK, Cero F, Brixen K, Nissen-Meyer LS, Gautvik KM. Abnormal muscle and hematopoietic gene expression may be important for clinical morbidity in primary hyperparathyroidism. Am J Physiol Endocrinol Metab 2007; 292:E1465-73. [PMID: 17227961 DOI: 10.1152/ajpendo.00487.2006] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
In primary hyperparathyroidism (PHPT), excess PTH secretion by adenomatous or hyperplastic parathyroid glands leads to elevated serum [Ca(2+)]. Patients present complex symptoms of muscular fatigue, various neuropsychiatric, neuromuscular, and cardiovascular manifestations, and, in advanced disease, kidney stones and metabolic bone disease. Our objective was to characterize changes in muscle and hematopoietic gene expression in patients with reversible mild PHPT after parathyroidectomy and possibly link molecular pathology to symptoms. Global mRNA profiling using Affymetrix gene chips was carried out in biopsies obtained before and 1 yr after parathyroidectomy in seven patients discovered by routine blood [Ca(2+)] screening. The tissue distribution of PTH receptor (PTHR1 and PTHR2) mRNAs were quantitated using real-time RT-PCR in unrelated persons to define PTH target tissues. Of about 10,000 expressed genes, 175 muscle, 169 hematological, and 99 bone-associated mRNAs were affected. Notably, the major part of muscle-related mRNAs was increased whereas hematological mRNAs were predominantly decreased during disease. Functional and molecular network analysis demonstrated major alterations of several tissue characteristic groups of mRNAs as well as those belonging to common cell signaling and major metabolic pathways. PTHR1 and PTHR2 mRNAs were more abundantly expressed in muscle and brain than in hematopoietic cells. We suggest that sustained stimulation of PTH receptors present in brain, muscle, and hematopoietic cells have to be considered as one independent, important cause of molecular disease in PHPT leading to profound alterations in gene expression that may help explain symptoms like muscle fatigue, cardiovascular pathology, and precipitation of psychiatric illness.
Collapse
MESH Headings
- Aged
- Biopsy
- Gene Expression Regulation
- Hematopoietic System/metabolism
- Hematopoietic System/physiology
- Humans
- Hyperparathyroidism, Primary/genetics
- Hyperparathyroidism, Primary/metabolism
- Middle Aged
- Muscles/metabolism
- Muscles/physiology
- Oligonucleotide Array Sequence Analysis
- Parathyroid Hormone/biosynthesis
- Parathyroid Hormone/genetics
- RNA, Messenger/biosynthesis
- RNA, Messenger/genetics
- Receptor, Parathyroid Hormone, Type 1/biosynthesis
- Receptor, Parathyroid Hormone, Type 1/genetics
- Receptor, Parathyroid Hormone, Type 2/biosynthesis
- Receptor, Parathyroid Hormone, Type 2/genetics
- Reverse Transcriptase Polymerase Chain Reaction
Collapse
Affiliation(s)
- Sjur Reppe
- Department of Medical Biochemistry, University of Oslo, Oslo, Norway
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Reseland JE, Reppe S, Larsen AM, Berner HS, Reinholt FP, Gautvik KM, Slaby I, Lyngstadaas SP. The effect of enamel matrix derivative on gene expression in osteoblasts. Eur J Oral Sci 2006; 114 Suppl 1:205-11; discussion 254-6, 381-2. [PMID: 16674687 DOI: 10.1111/j.1600-0722.2006.00333.x] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Observations that amelogenins, in the form of enamel matrix derivative (EMD), have a stimulatory effect on mesenchymal cells and tissues, and on the regeneration of alveolar bone, justified investigations into the effect of EMD on bone-forming cells. The binding and uptake of EMD in primary osteoblastic cells was characterized, and the effect of EMD on osteoblast gene expression, protein secretion, and mineralization was compared with the effect of parathyroid hormone (PTH). Although no specific receptor(s) has yet been identified, EMD appeared to be taken up by osteoblasts through clathrin-coated pits via the interaction with clathrin adaptor protein complex AP-2, the major mechanism of cargo sorting into coated pits in mammalian cells. EMD had a positive effect on factors involved in mineralization in vitro, causing an increased alkaline phosphatase (ALP) activity in the medium as well an as increased expression of osteocalcin and collagen type 1. Several hundred genes are regulated by EMD in primary human osteoblasts. There appear to be similarities between the effects of EMD and PTH on human osteoblasts. The expression pattern of several mRNAs and proteins upon EMD stimulation also indicates a secondary osteoclast stimulatory effect, suggesting that the osteogenic effect of EMD in vivo, at least partly, involves stimulation of bone remodelling.
Collapse
Affiliation(s)
- Janne E Reseland
- Oral Research Laboratory, Institute for Clinical Dentistry, University of Oslo, and Institute of Pathology, Rikshospitalet University Hospital, Oslo, Norway.
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Reppe S, Stilgren L, Olstad OK, Brixen K, Nissen-Meyer LS, Gautvik KM, Abrahamsen B. Gene expression profiles give insight into the molecular pathology of bone in primary hyperparathyroidism. Bone 2006; 39:189-98. [PMID: 16516570 DOI: 10.1016/j.bone.2005.12.020] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/16/2005] [Revised: 12/19/2005] [Accepted: 12/22/2005] [Indexed: 11/16/2022]
Abstract
Global gene expression profiling has been used to study the molecular mechanisms of increased bone remodeling caused by PHPT. This disease is a model for chronic over-stimulation of target organs by PTH due to an inappropriate overproduction of the hormone. Hyperactivity of osteoblasts and osteoclasts lead to increased calcium and phosphate mobilization from the skeleton and hypercalcaemia. The ensemble of genes that alter expression and thus is responsible for the effects of chronic PTH stimulation is today largely unknown. The differentiated gene expression profiles revealed characteristic molecular disease modalities which define the bone remodeling abnormalities occurring in PTH dependent osteodystrophy. We analyzed mRNAs in transiliacal bone biopsies from 7 patients with PHPT using Affymetrix HG-U133A Gene Chips containing more than 22000 different probe sets. Similar analyses of the global transcriptional activity were repeated in a second bone biopsy from the same patient taken one year after surgery and reversal of disease parameters. Real time PCR was carried out on many genes for corroboration of the results. Out of more than 14500 different genes examined, 99 which were related to bone and extra-cellular matrix, showed altered expression. Of these were 85 up- and 14 down-regulated before operation. The majority of regulated genes represented structural and adhesion proteins, but included also proteases and protease regulators which promote resorption. Increased expressions of collagen type 1 and osteocalcin mRNAs in disease reflecting the PTH anabolic action were paralleled by increased concentrations of these proteins in serum. In addition, genes encoding transcriptional factors and their regulators as well as cellular signal molecules were up-regulated during disease. The identified genetic signature represents the first extensive description of the ensemble of bone and matrix related mRNAs, which are regulated by chronic PTH action. These results identify the molecular basis for this skeletal disease, and provide new insight into this clinical condition with potential bearing on future treatment.
Collapse
Affiliation(s)
- Sjur Reppe
- University of Oslo, Department of Medical Biochemistry, P.O. Box 1112 Blindern, 0317 Oslo, Norway, and Department of Endocrinology, Odense University Hospital, Denmark.
| | | | | | | | | | | | | |
Collapse
|
37
|
Fjeldheim AK, Høvring PI, Løseth OP, Johansen PW, Glover JC, Matre V, Olstad OK, Reppe S, Gordeladze JO, Walaas SI, Gautvik KM. Thyrotrophin-releasing hormone receptor 1 and prothyrotrophin-releasing hormone mRNA expression in the central nervous system are regulated by suckling in lactating rats. Eur J Endocrinol 2005; 152:791-803. [PMID: 15879366 DOI: 10.1530/eje.1.01902] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND The accepted function of the hypothalamic peptide, thyrotrophin-releasing hormone (TRH), is to initiate release of thyrotrophin (TSH) from the pituitary. A physiological role for TRH in lactating rats has not yet been established. METHODS Tissues were prepared from random-cycling and lactating rats and analysed using Northern blot, real time RT-PCR and quantitative in situ hybridisation. RESULTS This study demonstrates that TRH receptor 1 (TRHR1) mRNA expression is up-regulated in the pituitary and in discrete nuclei of the hypothalamus in lactating rats, while proTRH mRNA expression levels are increased only in the hypothalamus. The results were corroborated by quantitative in situ analysis of proTRH and TRHR1. Bromocriptine, which reduced prolactin (PRL) concentrations in plasma of lactating and nursing rats, also counteracted the suckling-induced increase in TRHR1 mRNA expression in the hypothalamus, but had an opposite effect in the pituitary. These changes were confined to the hypothalamus and the amygdala in the brain. CONCLUSIONS The present study shows that the mechanisms of suckling-induced lactation involve region-specific regulation of TRHR1 and proTRH mRNAs in the central nervous system notably at the hypothalamic level. The results demonstrate that continued suckling is critical to maintain plasma prolactin (PRL) levels as well as proTRH and TRHR1 mRNA expression in the hypothalamus. Increased plasma PRL levels may have a positive modulatory role on the proTRH/TRHR1 system during suckling.
Collapse
Affiliation(s)
- Ase-Karine Fjeldheim
- Institute of Basic Medical Science, Department of Biochemistry, University of Oslo, PO Box 1112 Blindern, N-0317 Oslo, Norway
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Paulssen RH, Paulssen EJ, Gautvik KM. Electroporation of rat pituitary cells. Methods Mol Biol 2003; 48:123-31. [PMID: 8528385 DOI: 10.1385/0-89603-304-x:123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- R H Paulssen
- Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, USA
| | | | | |
Collapse
|
39
|
Matre V, Høvring PI, Fjeldheim AK, Helgeland L, Orvain C, Andersson KB, Gautvik KM, Gabrielsen OS. The human neuroendocrine thyrotropin-releasing hormone receptor promoter is activated by the haematopoietic transcription factor c-Myb. Biochem J 2003; 372:851-9. [PMID: 12628004 PMCID: PMC1223435 DOI: 10.1042/bj20030057] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2003] [Revised: 03/03/2003] [Accepted: 03/10/2003] [Indexed: 01/14/2023]
Abstract
Thyrotropin-releasing hormone (TRH) receptor (TRHR) is a G-protein-coupled receptor playing a crucial role in the anterior pituitary where it controls the synthesis and secretion of thyroid-stimulating hormone and prolactin. Its widespread presence not only in the central nervous system, but also in peripheral tissues, including thymus, indicates other important, but unknown, functions. One hypothesis is that the neuropeptide TRH could play a role in the immune system. We report here that the human TRHR promoter contains 11 putative response elements for the haematopoietic transcription factor c-Myb and is highly Myb-responsive in transfection assays. Analysis of Myb binding to putative response elements revealed one preferred binding site in intron 1 of the receptor gene. Transfection studies of promoter deletions confirmed that this high-affinity element is necessary for efficient Myb-dependent transactivation of reporter plasmids in CV-1 cells. The Myb-dependent activation of the TRHR promoter was strongly suppressed by expression of a dominant negative Myb-Engrailed fusion. In line with these observations, reverse transcriptase PCR analysis of rat tissues showed that the TRHR gene is expressed both in thymocytes and bone marrow. Furthermore, specific, high-affinity TRH agonist binding to cell-surface receptors was demonstrated in thymocytes and a haematopoietic cell line. Our findings imply a novel functional link between the neuroendocrine and the immune systems at the level of promoter regulation.
Collapse
Affiliation(s)
- Vilborg Matre
- Department of Biochemistry, University of Oslo, P.O. Box 1041 Blindern, Norway.
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Olstad OK, Gautvik VT, Reppe S, Rian E, Jemtland R, Ohlsson C, Bruland OS, Gautvik KM. Molecular heterogeneity in human osteosarcoma demonstrated by enriched mRNAs isolated by directional tag PCR subtraction cloning. Anticancer Res 2003; 23:2201-16. [PMID: 12894494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Abstract
Directional tag PCR subtractive hybridization was applied to construct a cDNA library generated from three different human osteosarcoma (OS) target cell lines (OHS, SaOS-2 and KPDXM) from which normal osteoblast (NO) sequences were subtracted. After two consecutive subtractive steps more than 98% of the common mRNAs species were depleted, leading to effective enrichment of the remaining target sequences. After differential screening of 960 clones, 81 candidates were further studied by Northern blot analysis and 73 represented separate mRNA species. Fifty-three of these showed enriched mRNA levels, of which 36 represented known and 17 not previously published cDNAs or EST sequences. The mRNAs showed a 1.4- to 504-fold enrichment compared to the mRNA levels in NO cells. The known mRNAs are: Ribosomal protein S11, KSP-37, Tethering factor SEC34, FXYD6, Alpha enolase, G-s-alpha, GPR85, DAF, RPL35A, GIF, TAPA-1, ANAPC11, DCI, hsp27, MRPS7 homolog, eIF p110 subunit, DPH2L, HMG-14, FB1 protein, chondroitin-6-sulphonase, calgizzarin, RNA polymerase II subunit, RPL13A, DHS, gp96, HHP2, acidic ribosomal phosphoprotein P2, ANT-2, ARF1, AFG3L2, SKD3, phosphoglucoisomerase, GST pi, CKI gamma 2, DNA polymerase delta small subunit and TRAP delta. Sections of human osteosarcoma biopsies and a xenograft were studied by in situ analysis. Seven cDNAs highly expressed in Northern blot analysis were tested. Their in situ expression differed between the xenograft and human sections as did that of collagen I. In the xenograft made from one of the target cell lines (OHS), a fair to strong representation of 3 cloned mRNAs was observed while collagen I mRNA was not detectable. We conclude that the molecular heterogeneity of these tumors is considerable. These results ought to have implications for future work to describe phenotypic subtypes with the aim of improving the diagnosis of human osteosarcomas.
Collapse
Affiliation(s)
- Ole K Olstad
- Department of Medical Biochemistry, Norwegian Radium Hospital, 0310 N-Oslo, Norway.
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Johansen PW, Paulssen RH, Bjøro T, Gautvik KM, Gordeladze JO. Distinct guanine nucleotide binding protein alpha-subunit receptor coupling in GH cell lines: effects of bromocriptine and hormones on effector enzyme modulation. Cell Physiol Biochem 2002; 11:339-52. [PMID: 11832659 DOI: 10.1159/000047820] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
The purpose of the present study was to elucidate how the dopamine agonist bromocriptine affected receptor-effector systems in GH cells by measuring adenylate cyclase (AC) and phospholipase C (PL-C) modulation in cell membrane preparations. To perturb the interaction between the receptor and G-protein, polyclonal antibodies reacting with the predicted C-terminal amino acid sequence of G-protein alpha-subunits were used. The effect of bromocriptine on secretagogue elicited prolactin (PRL) secretion from whole cells was also monitored. Bromocriptine inhibited the basal secretion of PRL in a dose dependent manner, and completely abolished both the thyroliberin (TRH) and the vasoactive intestinal peptide (VIP) stimulated PRL secretion in GH(3) cells. Maximal inhibitory effect on PRL egress elicited by both hormones was obtained at 10-50 microM of bromocriptine. Messenger RNAs for both the short and long form of the D(2) receptor (D(2)R) were demonstrated in all three GH cell lines using the RT-PCR technique, advocating that D(2)Rs are coupled to distinct G-proteins and, thus, probably being responsible for the observed effects of bromocriptine in these cell lines. Basal AC activity, as measured in membrane preparations of GH(3) cells, remained unaffected by bromocriptine treatment (10 microM), while TRH and VIP stimulated AC activities (175% and 350% of control values, respectively) were partially inhibited (by some 50%). This inhibitory effect of bromocriptine was completely and specifically abolished in the presence of an antiserum against G(i2)alpha. Basal PL-C activity was also unaffected by bromocriptine, while TRH stimulated PL-C activity (350% of control value) was inhibited by bromocriptine (10 microM) by approximately 50%. Immunoblocking of G(q/11)alpha, however, reduced the stimulatory effect of TRH on PL-C activation by some 65%, while an antiserum against G(o)alpha partly counteracted the inhibitory effect of bromocriptine (10 microM) on TRH stimulated PL-C activity. Thus, TRH dependent AC stimulation was counteracted by bromocriptine via G(i2). TRH activation of PL-C occurs via G(q/11), while inhibition by bromocriptine appears to involve G(o). These mechanisms probably account for the major part of the actions of bromocriptine, however, other not yet recognised intermediates may be involved.
Collapse
Affiliation(s)
- P W Johansen
- Department of Clinical Pharmacology, The National Hospital, University of Oslo, Oslo, Norway.
| | | | | | | | | |
Collapse
|
42
|
Reppe S, Rian E, Jemtland R, Olstad OK, Gautvik VT, Gautvik KM. Sox-4 messenger RNA is expressed in the embryonic growth plate and regulated via the parathyroid hormone/parathyroid hormone-related protein receptor in osteoblast-like cells. J Bone Miner Res 2000; 15:2402-12. [PMID: 11127205 DOI: 10.1359/jbmr.2000.15.12.2402] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Parathyroid hormone (PTH) and PTH-related protein (PTHrP) exert potent and diverse effects in cells of the osteoblastic and chondrocytic lineages. However, downstream mediators of these effects are characterized inadequately. We identified a complementary DNA (cDNA) clone encoding the 5' end of the transcription factor Sox-4, using a subtracted cDNA library enriched in PTH-stimulated genes from the human osteoblast-like cell line OHS. The SOX-4 gene is a member of a gene family (SOX and SRY) comprising transcription factors that bind to DNA through their high mobility group (HMG)-type binding domain, and previous reports have implicated Sox proteins in various developmental processes. In situ hybridization of fetal and neonatal mouse hindlimbs showed that Sox-4 messenger RNA (mRNA) was expressed most intensely in the zone of mineralizing cartilage where chondrocytes undergo hypertrophy, and by embryonic day 17 (ED17), after the primary ossification center was formed, its expression was detected only in the region of hypertrophic chondrocytes. Sox-4 mRNA was detected in osteoblast-like cells of both human and rodent origin. In OHS cells, physiological concentrations (10(-10)-10(-9) M) of human PTH 1-84 [hPTH(1-84)] and hPT(1-34), but not hPTH(3-84), stimulated Sox-4 mRNA expression in a time-dependent manner, indicating involvement of the PTH/PTHrP receptor. Sox-4 transcripts also were detected in various nonosteoblastic human cell lines and tissues, in a pattern similar to that previously reported in mice. The presence of Sox-4 mRNA in hypertrophic chondrocytes within the mouse epiphyseal growth plate at sites that overlap or are adjacent to target cells for PTH and PTHrP, and its strong up-regulation via activated PTH/PTHrP receptors in OHS cells, makes it a promising candidate for mediating downstream effects of PTH and PTHrP in bone.
Collapse
Affiliation(s)
- S Reppe
- Department of Medical Biochemistry, University of Oslo, Norway
| | | | | | | | | | | |
Collapse
|
43
|
Løseth OP, de Lecea L, Calbet M, Danielson PE, Gautvik V, Høvring PI, Walaas SI, Gautvik KM. Developmental regulation of two isoforms of Ca(2+)/calmodulin-dependent protein kinase I beta in rat brain. Brain Res 2000; 869:137-45. [PMID: 10865068 DOI: 10.1016/s0006-8993(00)02359-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Subtractive hybridization analysis of region-specific gene expression in brain has demonstrated a mRNA species enriched in rat hypothalamus [K.M. Gautvik, L. de Lecea, V.T. Gautvik, P.E. Danielson, P. Tranque, A. Dopazo, F.E. Bloom, J.G. Sutcliffe, Proc. Natl. Acad. Sci. USA 93 (1996) 8733-8738.]. We here show that this mRNA encodes a Ca(2+)/calmodulin-dependent (CaM) kinase belonging in the CaM kinase I beta subgroup. cDNA analysis showed that this enzyme was differentially spliced into two isoforms (designated beta1 and beta2) with distinct C-termini. The C-terminal of the translated CaM kinase I beta2 protein (38.5 kDa molecular size), contained 25 amino acid residues not present in the beta1 isoform. The two isoforms were differentially developmentally regulated, with the beta1 isoform being present in rat embryos from day 18 and the beta2 isoform being present from day 5 postnatally. In situ hybridization analysis of adult rat CNS showed CaM kinase I beta2 mRNA being enriched in the hypothalamus and the hippocampal formation. Expression was also observed in a number of ventral limbic structures and in the thalamus. Northern blot analysis showed additional expression of multiple beta2 isoforms in heart and skeletal muscle. The human mRNA showed a similar distribution. Our data suggest that the two isoforms of CaM kinase I beta, created by a splicing process occurring within a week around birth, may have distinct pre- and postnatal functions in a distinct set of CNS neurons and excitable tissues.
Collapse
Affiliation(s)
- O P Løseth
- Institute of Medical Biochemistry, University of Oslo, P.O. Box 1112 Blindern, 0317, Oslo, Norway.
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Jemtland R, Rian E, Olstad OK, Haug E, Bruland OS, Bucht E, Gautvik KM. Two human osteoblast-like osteosarcoma cell lines show distinct expression and differential regulation of parathyroid hormone-related protein. J Bone Miner Res 1999; 14:904-14. [PMID: 10352098 DOI: 10.1359/jbmr.1999.14.6.904] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Parathyroid hormone (PTH)-related protein (PTHrP) acts as a local regulator of osteoblast function via mechanisms that involve PTH/PTHrP receptors linked to protein kinase A (PKA) and C (PKC). However, the regulation of PTHrP production and mRNA expression in human osteoblasts is poorly understood. Here we have characterized alternative PTHrP mRNA 3' splicing variants, encoding PTHrP isoforms of 139, 141, and 173 amino acids, and studied the regulation of PTHrP and its mRNAs by activated PKA and PKC in two human osteoblast-like cell lines (KPDXM and TPXM). Using exon-specific Northern analysis and reverse transcriptase-coupled polymerase chain reaction, we identified mRNAs encoding PTHrP(1-139) and PTHrP(1-141) in both cell lines. PTHrP(1-139) mRNAs predominated in TPXM cells and PTHrP(1-173) mRNAs were only detected in TPXM cells. Activation of PKA or PKC resulted in different effects on PTHrP and its mRNAs in the two cell lines. In TPXM cells, peptide-specific immunoassays detected high basal levels of PTHrP, increasing by 2-fold in cell extracts and 4-fold in culture media at 7 h and 24 h after exposure to forskolin, respectively, paralleling changes in PTHrP mRNA expression. Phorbol ester 12-O-tetradecanoyl-phorbol 13-acetate (TPA), a PKC activator, had no effect. In KPDXM cells, PTHrP was not detected in culture media under basal experimental conditions, and barely detectable amounts were present in cell extracts of TPA-treated cells, although the mRNA levels increased substantially in response to TPA. In the responsive cell lines, the effects on mRNA levels were dose dependent, and increased by 6.9- to 10.5-fold and 2.0- to 4.1-fold at 4 h in TPXM and KPDXM cells after exposure to 10 microM forskolin and 150 nM TPA, respectively. PTHrP mRNA levels then declined but were sustained above controls also at 12 h in both cell lines, albeit at considerably higher levels in TPXM cells. The different responsiveness to agents activating PKA- and PKC-dependent pathways may depend on the cellular state of differentiation, or alternatively, cancer cell line-specific defects. Our data demonstrating distinct differences in mRNA species and the amounts of PTHrP produced by the two cell lines as compared with roughly equivalent overall mRNA levels may suggest that post-transcriptional mechanisms play an important role in limiting the production of intracellular and secreted PTHrPs in human osteoblastic cells.
Collapse
Affiliation(s)
- R Jemtland
- Institute of Medical Biochemistry, University of Oslo, Oslo, Norway
| | | | | | | | | | | | | |
Collapse
|
45
|
Høvring PI, Matre V, Fjeldheim AK, Loseth OP, Gautvik KM. Transcription of the human thyrotropin-releasing hormone receptor gene-analysis of basal promoter elements and glucocorticoid response elements. Biochem Biophys Res Commun 1999; 257:829-34. [PMID: 10208868 DOI: 10.1006/bbrc.1999.0545] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The gene for the human thyrotropin-releasing hormone receptor (TRHR) spans 35 kb and contains three exons and two introns (Matre et al. (1999) J. Neurochem. 72, 1-11). Despite a reported transcription start site (TSS) mapped to position -885 upstream of the translation initiation codon (Iwasaki et al. (1996) J. Biol. Chem. 271, 22183-8), we found cell type specific promoter activity directed by a fragment downstream of this site (-770 to +1). To elucidate the basis for this unexpected activity, we analyzed basal promoter elements in this region of the gene. One divergent TATA box, TTTAAA in position -759, was found by mutational analysis to be critical for promoter activity, providing a likely explanation for the basal activity observed. This proximal region apparently contains several promoter elements, including Pit-1 binding sequences within the first intron of the TRHR gene as previously reported. Here we describe the analysis of two putative glucocorticoid response elements (GREs) that we identified in this region, one (distal) half site overlapping the proposed TSS at -885 and one (proximal) full site within the first intron at position -624. Accordingly, stimulation of rat pituitary GH3 and GH4C1 cells with dexamethasone strongly enhanced transcription activity of a reporter construct containing the distal GRE half site and the proximal GRE site. Both sites bound the glucocorticoid receptor (GR) in a specific manner. Deletion of the distal GRE half site abolished the dexamethasone induction of CAT transcription, as did mutations in the proximal site. We therefore conclude that both sites are necessary for regulation of the TRHR gene transcription by glucocorticoids.
Collapse
Affiliation(s)
- P I Høvring
- Institute of Medical Biochemistry, University of Oslo, Blindern, Oslo, 0317, Norway.
| | | | | | | | | |
Collapse
|
46
|
Matre V, Høvring PI, Orstavik S, Frengen E, Rian E, Velickovic Z, Murray-McIntosh RP, Gautvik KM. Structural and functional organization of the gene encoding the human thyrotropin-releasing hormone receptor. J Neurochem 1999; 72:40-50. [PMID: 9886052 DOI: 10.1046/j.1471-4159.1999.0720040.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The thyrotropin-releasing hormone (TRH) receptor (TRHR) is widely distributed throughout the central and peripheral nervous systems. In addition to its role in controlling the synthesis and secretion of thyroid-stimulating hormone and prolactin from the anterior pituitary, TRH is believed to act as a neurotransmitter as well as a neuromodulator. We have isolated genomic lambda and P1-derived artificial chromosome clones encoding the human TRHR. The gene was found to be 35 kb with three exons and two introns. A 541-bp intron 1 (-629 to -89 relative to the translation start site) is conserved between human and mouse. A large intron 2 of 31 kb disrupts the open reading frame (starting in position +790) in the sequence encoding the supposed junction between the third intracellular loop and the putative sixth transmembrane domain. A similar intron was found in chimpanzee and sheep but not in rat and mouse. Promoter analysis of upstream regions demonstrated cell type-specific reporter activation, and sequencing of 2.5 kb of the promoter revealed putative cis-acting regulatory elements for several transcription factors that may contribute to the regulation of the TRHR gene expression. Functional analysis of potential response elements for the anterior pituitary-specific transcription factor Pit-1 revealed cell type-specific binding that was competed out with a Pit-1 response element from the GH gene promoter.
Collapse
Affiliation(s)
- V Matre
- Institute of Medical Biochemistry, University of Oslo, Norway
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Røttingen JA, Thorsby P, Seem C, Gautvik KM. [Medical research at Norwegian universities]. Tidsskr Nor Laegeforen 1998; 118:2339-43. [PMID: 9691802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
This study shows that Norwegian medical research suffers from lack of both public funds and recruitment, as well as being affected by the following major factors. Norway uses less of its GNP on R&D than other Western countries and less than the OECD average. Medical research in particular receives less financial support than in any of the other Nordic countries. Norwegian medical researchers publish less material and are cited less often than their colleagues in comparable countries. More than half of the medically trained scientific staff in Norway's four medical faculties will retire during the next decade and today there are many vacant positions in academic medicine because there are not enough competent applicants to fill them. The percentage of M.D.s among professors and lecturers has fallen, and a continued decline in preclinical and laboratory medicine and in public health is predicted. This percentage has also decreased among Ph.D. students, while the age at which medical doctors dissertate has increased and is higher than for other Ph.D.s. The number of medical students doing research has fallen in recent years, and the number of doctoral theses has not increased as much in medicine as in other fields. There are significant differences between the salaries paid in medical science and those paid in clinical medicine. Lack of resources and low salaries keep doctors from pursuing a career in academic medicine. In conclusion, if Norway is to be visible in the field of international medical science, this negative trend must be reversed and medical research and academic medicine revitalised.
Collapse
|
48
|
de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS, Frankel WN, van den Pol AN, Bloom FE, Gautvik KM, Sutcliffe JG. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998; 95:322-7. [PMID: 9419374 PMCID: PMC18213 DOI: 10.1073/pnas.95.1.322] [Citation(s) in RCA: 2777] [Impact Index Per Article: 106.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
We describe a hypothalamus-specific mRNA that encodes preprohypocretin, the putative precursor of a pair of peptides that share substantial amino acid identities with the gut hormone secretin. The hypocretin (Hcrt) protein products are restricted to neuronal cell bodies of the dorsal and lateral hypothalamic areas. The fibers of these neurons are widespread throughout the posterior hypothalamus and project to multiple targets in other areas, including brainstem and thalamus. Hcrt immunoreactivity is associated with large granular vesicles at synapses. One of the Hcrt peptides was excitatory when applied to cultured, synaptically coupled hypothalamic neurons, but not hippocampal neurons. These observations suggest that the hypocretins function within the CNS as neurotransmitters.
Collapse
Affiliation(s)
- L de Lecea
- Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Olstad OK, Reppe S, Loseth OP, Jemtland R, Gautvik KM. Binding and cyclic AMP stimulation by N-terminally deleted human PTHs (3-84 and 4-84) in a homologous ligand receptor system. J Bone Miner Res 1997; 12:1348-57. [PMID: 9286750 DOI: 10.1359/jbmr.1997.12.9.1348] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We have produced in yeast two human parathyroid hormone (hPTH) analogs with amino-terminal deletions, hPTH(3-84) and hPTH(4-84), employing the mating factor alpha (MF alpha) expression system. The authenticity of the polypeptides was demonstrated by amino-terminal analysis, amino acid composition, and molecular mass analysis. In cells (LLC-PK1) transfected with the human PTH/parathyroid hormone-related protein (PTHrP) receptor, using [125I-Tyr36]chickenPTHrP(1-36)NH2 as radioligand, binding studies revealed dissociation constants at equilibrium (Kd) for hPTH(3-84) and hPTH(4-84) of 4.7 and 8.0 nM, respectively, only slightly higher than natural recombinant hPTH(1-84) Kd = 2.3 nM). In comparison, [Nle8,18,Tyr34]bovinePTH(3-34)NH2 and [Tyr36]cPTHrP(1-36)NH2 showed equal Kd's of 1.9 nM. Neither of the N-terminally deleted hPTH analogs showed any detectable stimulation of cAMP production in the cells at concentrations below 20 nM. At supersaturated concentrations (500 nM) with receptor occupancy of more than 95% these hPTH analogs revealed about 15% rest agonism compared with that of hPTH(1-84). hPTH(1-84) and [Tyr36]cPTHrP(1-36)NH2 showed an equal half maximal cyclic adenosine monophosphate (cAMP) stimulation of about 0.8 and 0.7 nM, respectively. The hPTH analogs did not show any ability to antagonize cellular cAMP production induced by either hPTH or [Tyr36]cPTHrP(1-36)NH2. [Nle8,18,Tyr34]bPTH(3-34)NH2 did also not antagonize cAMP stimulation by hPTH, but inhibited [Tyr36]cPTHrP(1-36)NH2-induced cAMP production by 40% when present at a 1000 M excess. These distinct results related to PTH and PTHrP from different species are important to consider in experiments evaluating potential hPTH or PTHrP antagonism, and employment of a hPTH/PTHrP receptor model is a requirement.
Collapse
Affiliation(s)
- O K Olstad
- Institute of Medical Biochemistry, University of Oslo, Norway
| | | | | | | | | |
Collapse
|
50
|
Gautvik KM, de Lecea L, Gautvik VT, Danielson PE, Tranque P, Dopazo A, Bloom FE, Sutcliffe JG. Overview of the most prevalent hypothalamus-specific mRNAs, as identified by directional tag PCR subtraction. Proc Natl Acad Sci U S A 1996; 93:8733-8. [PMID: 8710940 PMCID: PMC38742 DOI: 10.1073/pnas.93.16.8733] [Citation(s) in RCA: 223] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
We applied the directional tag PCR subtractive hybridization method to construct a rat hypothalamic cDNA library from which cerebellar and hippocampal sequences had been depleted, enriching 20-30-fold for sequences expressed selectively in the hypothalamus. We studied a sample of 94 clones selected for enrichment in the subtracted library. These clones corresponded to 43 distinct mRNA species, about half of which were novel. Thirty-eight of these 43 mRNAs (corresponding to 85 of the clones in the sample) exhibited enrichment in the hypothalamus; 23 were highly enriched. In situ hybridization studies revealed that one novel species was restricted to cells in a small bilaterally symmetric area of the paraventricular hypothalamus. Other novel mRNAs showed substantial enrichment in basal diencephalic structures, particularly the hypothalamus, without restriction to single hypothalamic nuclei. The data suggest that the hypothalamus utilizes at least two distinct strategies for employing its selectively expressed proteins. Secretory neuropeptides utilized for intercellular communication are produced by functionally discrete nuclei, while several other proteins are shared by structures that are unrelated in their physiological roles but may share biochemical systems.
Collapse
Affiliation(s)
- K M Gautvik
- Department of Molecular Biology, Scripps Research Institute, La Jolla, CA 92037, USA
| | | | | | | | | | | | | | | |
Collapse
|